https://curecurrent.com/trials/neoadjuvant-adjuvant-cadonilimab-plus-chemotherapy-in-patients-with-resectable-pd-l1-negative-nsclc-46001https://curecurrent.com/trials/durvalumab-long-term-safety-and-efficacy-study-46002https://curecurrent.com/trials/lorlatinib-in-alk-inhibitor-treated-unresectable-advanced-recurrent-alk-positive-non-small-cell-lung-cancer-patients-in-46003https://curecurrent.com/trials/a-real-world-assessment-of-the-demographic-clinical-characteristics-and-outcomes-of-a-brazilian-cohort-of-previously-unt-46004https://curecurrent.com/trials/a-study-of-ibi363-in-subjects-with-advanced-solid-malignancies-46005https://curecurrent.com/trials/application-of-dce-mri-based-on-4d-freebreathing-in-predicting-the-efficacy-of-immune-and-targeted-therapy-in-lung-cance-46006https://curecurrent.com/trials/individualized-lung-tumor-stereotactic-ablative-radiotherapy-isabr-46007https://curecurrent.com/trials/integrating-machine-learning-for-prognostic-prediction-in-stage-i-nsclc-by-ct-images-and-pathological-factors-46008https://curecurrent.com/trials/new-method-to-differentiate-benign-and-malignant-pulmonary-nodules-46009https://curecurrent.com/trials/the-diagnostic-value-of-bronchoscopic-needle-based-confocal-laser-endomicroscopy-ncle-as-a-real-time-detection-tool-for-46010https://curecurrent.com/trials/a-study-of-pm8002-in-combination-with-chemotherapy-in-patients-with-sclc-46011https://curecurrent.com/trials/cross-sectorial-rehabilitation-of-patients-with-lung-cancer-46012https://curecurrent.com/trials/irinotecan-liposome-ii-or-etoposide-combined-with-adebrelimab-and-carboplatin-in-the-treatment-of-es-sclc-46013https://curecurrent.com/trials/predictive-value-of-multiparametric-dynamic-wb-18f-fdg-pet-imaging-on-a-lafov-system-for-first-line-chemo-immunotherapy-46014https://curecurrent.com/trials/a-randomized-placebo-controlled-study-to-evaluate-the-safety-and-potential-efficacy-of-ms-20-in-combination-with-pembrol-46015https://curecurrent.com/trials/multicenter-analysis-of-different-approaches-in-segmentectomies-in-early-stage-lung-cancer-46016https://curecurrent.com/trials/dose-individualization-of-pemetrexed-improve-i-46017https://curecurrent.com/trials/clinical-trial-of-lung-cancer-chemoprevention-with-sulforaphane-in-former-smokers-46018https://curecurrent.com/trials/imaging-of-chemotherapy-induced-morphological-and-functional-lung-changes-in-childhood-all-and-hd-46019https://curecurrent.com/trials/a-first-in-human-dose-escalation-study-of-jab-3068-shp2-inhibitor-in-adult-patients-with-advanced-solid-tumors-46020https://curecurrent.com/trials/mrna-neoantigen-vaccine-in-non-small-cell-lung-cancer-46021https://curecurrent.com/trials/a-phase-i-iia-study-of-uv1-vaccination-in-patients-with-non-small-cell-lung-cancer-46022https://curecurrent.com/trials/study-of-tislelizumab-and-platinum-based-chemotherapy-combination-with-h1-receptor-antagonist-diphenhydramine-in-advance-46023https://curecurrent.com/trials/dose-escalation-study-of-zg006-in-participants-with-advanced-small-cell-lung-cancer-or-neuroendocrine-carcinoma-followed-46024https://curecurrent.com/trials/a-clinical-study-of-jmt101-in-combination-with-osimertinib-versus-osimertinib-alone-as-first-line-treatment-for-patients-46025https://curecurrent.com/trials/a-study-comparing-sb8-and-avastin-in-patients-with-advanced-non-squamous-non-small-cell-lung-cancer-46026https://curecurrent.com/trials/adebrelimab-plus-chemo-and-recaticimab-in-perioperative-treatment-of-resectable-nsclc-46027https://curecurrent.com/trials/molecular-subtyping-of-extensive-stage-small-cell-lung-cancer-and-relevent-clinical-significance-46028https://curecurrent.com/trials/liquid-biopsy-for-early-non-small-lung-cancer-detection-46029https://curecurrent.com/trials/improvement-of-quality-of-life-qol-using-preference-oriented-qolmonitoring-in-patients-with-lung-cancer-46030https://curecurrent.com/trials/a-multicenter-real-world-clinical-study-on-the-efficacy-and-safety-of-ensartinib-as-neoadjuvant-treatment-for-anaplastic-46031https://curecurrent.com/trials/adagrasib-in-combination-with-bi-1701963-in-patients-with-cancer-krystal-14-46032https://curecurrent.com/trials/neoadjuvant-envafolimab-plus-disitamab-vedotin-and-carboplatin-in-resectable-her2-mutant-non-small-cell-lung-cancer-46033https://curecurrent.com/trials/clinical-outcomes-of-patients-with-resectable-non-small-cell-lung-cancer-receiving-neoadjuvant-nivolumab-plus-chemothera-46034https://curecurrent.com/trials/assessing-the-effect-of-dzd9008-on-the-pharmacokinetics-of-the-cocktail-probes-representative-for-cyp3a4-p-gp-bcrp-and-o-46035https://curecurrent.com/trials/machine-learning-for-predicting-and-managing-quality-of-life-in-lung-cancer-immunotherapy-patients-46036https://curecurrent.com/trials/a-study-developing-a-non-invasive-urine-based-proteomic-model-for-early-lung-cancer-detection-46037https://curecurrent.com/trials/the-therapeutic-effect-of-immunotherapy-in-patients-with-advanced-lung-squamous-carcinoma-46038https://curecurrent.com/trials/pre-operative-immuno-modulatory-sbrt-poims-trial-a-pilot-trial-in-early-stage-nsclc-46039https://curecurrent.com/trials/mr-linac-guided-adaptive-fsrt-for-brain-metastases-from-non-small-cell-lung-cancer-46040https://curecurrent.com/trials/plasma-exosomes-reveal-the-efficacy-of-targeted-therapy-in-patients-with-egfr-mutation-in-lung-adenocarcinoma-46041https://curecurrent.com/trials/shp2-inhibitor-bbp-398-in-combination-with-nivolumab-in-patients-with-advanced-non-small-cell-lung-cancer-with-a-kras-mu-46042https://curecurrent.com/trials/randomized-customized-adjuvant-chemotherapy-gecp-scat-46043https://curecurrent.com/trials/a-study-in-participants-with-first-line-nivolumab-plus-ipilimumb-therapy-combined-with-two-cycles-of-chemotherapy-for-me-46044https://curecurrent.com/trials/glycoprotein-in-immunotherapy-response-and-efficacy-prediction-of-lung-cancer-46045https://curecurrent.com/trials/an-observational-study-of-predictors-and-outcomes-of-lung-cancer-in-never-smokers-in-the-uk-46046https://curecurrent.com/trials/a-phase-2-clinical-study-of-combination-therapy-with-absk043-and-firmonertinib-46047https://curecurrent.com/trials/tumor-specific-t-cells-in-lung-cancer-46048https://curecurrent.com/trials/lurbinectedin-or-in-combination-with-irinotecan-versus-topotecan-in-patients-with-relapsed-sclc-46049https://curecurrent.com/trials/shp2-inhibitor-bbp-398-in-combination-with-sotorasib-in-patients-with-advanced-solid-tumors-and-a-kras-g12c-mutation-46050https://curecurrent.com/trials/clinical-trial-to-assess-bioequivalence-of-lazertinib-between-two-formulations-in-healthy-volunteers-46051https://curecurrent.com/trials/evaluation-of-the-efficacy-and-safety-of-furmonertinib-combined-with-bevacizumab-as-first-line-treatment-for-egfr-positi-46052https://curecurrent.com/trials/efficacy-and-safety-of-vorolanib-monotherapy-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung-cancer-pa-46053https://curecurrent.com/trials/olaparib-in-treating-patients-with-relapsed-or-refractory-advanced-solid-tumors-non-hodgkin-lymphoma-or-histiocytic-diso-46054https://curecurrent.com/trials/a-phase-i-ii-multicenter-open-label-study-of-egfrmut-tki-egf816-administered-orally-in-adult-patients-with-egfrmut-solid-46055https://curecurrent.com/trials/neoadjuvant-nimotuzumab-plus-gemcitabine-and-carboplatin-in-unresectable-stage-iii-squamous-cell-lung-carcinoma-46056https://curecurrent.com/trials/efficacy-and-safety-of-covid-19-vaccine-in-cancer-patients-46057https://curecurrent.com/trials/the-level-of-patient-participation-in-lung-and-esophageal-cancer-patients-treated-with-definitive-radiochemotherapy-46058https://curecurrent.com/trials/aumolertinib-in-egfr-mutant-resected-stage-ib-iiia-nsclc-aeresa-46059https://curecurrent.com/trials/apatinib-plus-chemotherapy-versus-chemotherapy-as-first-line-treatment-for-advanced-nsclc-46060https://curecurrent.com/trials/lymphocyte-depletion-and-change-in-lymphocyte-functionality-46061https://curecurrent.com/trials/first-in-human-study-for-the-assessment-of-safety-and-initial-performance-of-the-eas1-system-46062https://curecurrent.com/trials/neoadjuvant-gefitinib-followed-by-surgery-and-gefitinib-in-unresectable-stage-iii-nsclc-with-egfr-mutations-46063https://curecurrent.com/trials/a-study-of-asp8273-vs-erlotinib-or-gefitinib-in-first-line-treatment-of-patients-with-stage-iiib-iv-non-small-cell-lung-46064https://curecurrent.com/trials/a-study-of-mt027-in-patients-with-pleural-malignant-tumors-46065https://curecurrent.com/trials/cognitive-screening-in-lung-cancer-patients-46066https://curecurrent.com/trials/ono-4538-study-in-patients-with-advanced-non-small-cell-lung-cancer-46067https://curecurrent.com/trials/stereotactic-body-radiotherapy-for-lung-lesions-with-markerless-tracking-mlt-on-the-vero-sbrt-system-46068https://curecurrent.com/trials/study-on-prevalence-and-impact-of-brain-metastases-on-survival-in-lung-cancer-by-line-of-treatment-46069https://curecurrent.com/trials/vactosertib-in-combination-with-pembrolizumab-for-pd-l1-positive-non-small-cell-lung-cancer-nsclc-subjects-46070https://curecurrent.com/trials/sym024-monotherapy-and-in-combination-with-sym021-in-patients-with-advanced-solid-tumor-malignancies-46071https://curecurrent.com/trials/mass-evaluation-of-lateral-flow-immunoassays-for-the-detection-of-sars-cov-2-covid-19-antibodies-46072https://curecurrent.com/trials/a-study-to-evaluate-immunotherapy-combinations-in-participants-with-lung-cancer-46073https://curecurrent.com/trials/phase-3-clinical-study-of-chiauranib-capsule-in-patients-with-small-cell-lung-cancer-46074https://curecurrent.com/trials/impact-of-patient-centered-approach-for-communicating-coronary-calcium-on-cardiovascular-health-46075https://curecurrent.com/trials/evaluation-ctdna-in-patients-of-non-small-cell-lung-cancer-following-resection-46076https://curecurrent.com/trials/toripalimab-combined-with-gemcitabine-and-cisplatin-gemcis-as-preoperative-neoadjuvant-therapy-for-resectable-intrahepat-46077https://curecurrent.com/trials/neoadjuvant-js001-or-js001-in-combination-with-pemetrexed-and-carboplatin-in-resectable-nsclc-46078https://curecurrent.com/trials/safety-and-effectiveness-of-abm-168-in-adults-with-advanced-solid-tumors-46079https://curecurrent.com/trials/korean-registry-of-non-small-cell-lung-cancer-patients-with-egfr-mutation-46080https://curecurrent.com/trials/peripheral-ebus-with-rose-vs-no-rose-slim-bronchoscope-without-guide-sheath-vs-standard-bronchoscope-with-guide-sheath-46081https://curecurrent.com/trials/a-trial-of-sintilimab-plus-anlotinib-for-metastatic-nsclc-after-first-line-pd-1-inhibitor-46082https://curecurrent.com/trials/addition-of-thoracic-consolidation-radiotherapy-to-the-maintenance-immunotherapy-for-es-sclc-stone-001-46083https://curecurrent.com/trials/chemotherapy-plus-immunotherapy-combined-with-sbrt-as-neoadjuvant-therapy-for-patients-with-resectable-nsclc-46084https://curecurrent.com/trials/the-summit-study-a-cancer-screening-study-46085https://curecurrent.com/trials/chemotherapy-in-patients-with-relapsed-small-cell-lung-cancer-in-combination-with-allopurinol-and-mycophenolate-clamp-tr-46086https://curecurrent.com/trials/real-world-evidence-of-long-term-safety-and-efficacy-in-patients-treated-with-durvalumab-after-concurrent-chemoradiation-46087https://curecurrent.com/trials/non-linear-multimodal-microendoscopy-for-lung-cancer-pathology-46088https://curecurrent.com/trials/feasibility-of-mobile-ct-assisted-bronchoscopy-for-the-diagnosis-of-lung-lesion-46089https://curecurrent.com/trials/neo-adjuvant-immunotherapy-with-nivolumab-for-non-small-cell-lung-cancer-patients-46090https://curecurrent.com/trials/tumor-treating-fields-ttf-in-combination-with-stereotactic-radiosurgery-srs-for-brain-metastases-from-non-small-cell-lun-46091https://curecurrent.com/trials/pet-imaging-of-cancer-patients-using-68ga-dota-siglec-9-46092https://curecurrent.com/trials/exercise-to-boost-immunity-in-advanced-cancer-46093https://curecurrent.com/trials/ablation-of-pulmonary-oligometastasis-combined-with-system-for-advanced-hepatocellular-carcinoma-46094https://curecurrent.com/trials/pembrolizumab-for-metastatic-nsclc-patients-expressing-pd-l1-who-have-their-own-pdx-46095https://curecurrent.com/trials/exploring-the-mechanism-of-primary-resistance-to-third-generation-egfr-tkis-as-first-line-treatment-in-egfr-positive-adv-46096https://curecurrent.com/trials/a-prospective-non-interventional-cohort-study-of-subsolid-pulmonary-nodules-46097https://curecurrent.com/trials/a-tailored-screening-and-smoking-cessation-program-for-the-lgbtq-community-of-seattle-46098https://curecurrent.com/trials/analysis-of-rats-vats-and-open-lung-resections-after-neoadjuvant-chemo-immunotherapy-in-patients-performed-in-five-refer-46099https://curecurrent.com/trials/minimal-residual-disease-guiding-adjuvant-therapy-in-stage-i-nsclc-46100https://curecurrent.com/trials/a-study-of-abm-1310-in-patients-with-braf-v600-mutant-advanced-solid-tumors-46101https://curecurrent.com/trials/a-multicountry-multicentre-non-interventional-retrospective-study-to-determine-real-world-treatment-patterns-and-associa-46102https://curecurrent.com/trials/prevention-of-smoking-related-diseases-46103https://curecurrent.com/trials/molecular-analysis-and-treatment-options-of-sclc-46104https://curecurrent.com/trials/the-lymphocytic-infiltrate-of-lung-tumors-46105https://curecurrent.com/trials/evaluating-the-potential-of-large-language-models-for-respiratory-disease-consultations-46106https://curecurrent.com/trials/rsv-vaccination-in-immunocompromised-patients-46107https://curecurrent.com/trials/a-study-of-asp2215-in-combination-with-erlotinib-in-subjects-with-epidermal-growth-factor-receptor-egfr-activating-mutat-46108https://curecurrent.com/trials/robotic-assisted-major-lung-resection-in-elderly-patients-46109https://curecurrent.com/trials/quantitative-lung-cancer-screening-46110https://curecurrent.com/trials/durvalumab-plus-chemotherapy-in-es-sclc-oriental-46111https://curecurrent.com/trials/the-efficacy-of-shear-wave-elastography-guided-aspiration-and-biopsy-for-diagnosis-in-lung-tumor-46112https://curecurrent.com/trials/study-of-bebt-109-in-subjects-with-egfr-exon-20-insertion-mutations-non-small-cell-lung-cancer-46113https://curecurrent.com/trials/a-trial-with-chemotherapy-immunotherapy-and-radiotherapy-for-patients-with-newly-diagnosed-stage-iv-small-cell-lung-canc-46114https://curecurrent.com/trials/master-protocol-to-assess-safety-and-dose-of-first-time-in-human-next-generation-engineered-t-cells-in-ny-eso-1-and-or-l-46115https://curecurrent.com/trials/value-based-medicine-vbm-for-lung-cancer-46116https://curecurrent.com/trials/cadonilimab-combined-with-stereotactic-radiotherapy-as-second-line-treatment-for-brain-metastases-46117https://curecurrent.com/trials/aumolertinib-with-or-without-chemotherapy-as-1st-line-treatment-in-locally-advanced-or-metastatic-non-small-cell-lung-ca-46118https://curecurrent.com/trials/behavioral-relaxation-approaches-for-insomnia-in-lung-cancer-patients-46119https://curecurrent.com/trials/radiolabelled-nectin-4-targeted-lmw-probe-pet-ct-in-patients-with-lung-lesions-46120https://curecurrent.com/trials/a-study-of-ndi-1150-101-in-patients-with-solid-tumors-46121https://curecurrent.com/trials/tobacco-treatment-in-the-context-of-lung-cancer-screening-46122https://curecurrent.com/trials/surveillance-after-extremity-tumor-surgery-46123https://curecurrent.com/trials/phase-ii-clinical-study-of-adebrelimab-combined-with-apatinib-in-the-treatment-of-locally-advanced-non-small-cell-lung-c-46124https://curecurrent.com/trials/supportive-care-mobile-application-for-patients-with-nsclc-46125https://curecurrent.com/trials/study-of-pemetrexed-platinum-chemotherapy-with-or-without-pembrolizumab-mk-3475-in-adults-with-tyrosine-kinase-inhibitor-46126https://curecurrent.com/trials/efficacy-and-safety-of-first-line-treatment-for-extensive-stage-small-cell-lung-cancer-using-a-combination-therapy-of-tr-46127https://curecurrent.com/trials/predictive-multimodal-signatures-associated-with-response-to-treatment-and-prognosis-of-patients-with-stage-iv-non-small-46128https://curecurrent.com/trials/a-phase-1-dose-escalation-study-of-osi-906-and-erlotinib-tarceva-46129https://curecurrent.com/trials/a-study-of-asp8273-in-epidermal-growth-factor-receptor-egfr-tyrosine-kinase-inhibitor-na-ve-patients-with-non-small-cell-46130https://curecurrent.com/trials/cerebrospinal-fluid-immune-microenvironment-mechanism-in-anaplastic-lymphoma-kinase-positive-lung-cancer-patients-46131https://curecurrent.com/trials/a-study-of-asp8273-in-subjects-with-non-small-cell-lung-cancer-nsclc-harboring-epidermal-growth-factor-receptor-egfr-mut-46132https://curecurrent.com/trials/amg510-sotorasib-plus-lenvatinib-as-second-line-treatment-in-patients-with-krasg12c-mutant-metastatic-nsclc-46133https://curecurrent.com/trials/afatinib-with-ct-and-rt-for-egfr-mutant-nsclc-46134https://curecurrent.com/trials/the-detection-of-circulating-tumor-cells-ctc-in-patients-with-nsclc-undergoing-definitive-radiotherapy-or-chemoradiother-46135https://curecurrent.com/trials/study-of-high-efficient-killing-cell-therapy-for-advanced-nsclc-46136https://curecurrent.com/trials/efficacy-study-of-nivolumab-compared-to-docetaxel-in-subjects-previously-treated-with-advanced-or-metastatic-non-small-c-46137https://curecurrent.com/trials/a-phase-2-clinical-study-of-absk061-and-absk043-46138https://curecurrent.com/trials/preoperative-sintilimab-combined-with-bevacizumab-and-chemotherapy-for-resectable-non-small-cell-lung-cancer-46139https://curecurrent.com/trials/a-trial-to-find-the-safe-dose-for-bi-891065-alone-and-in-combination-with-bi-754091-in-patients-with-incurable-tumours-o-46140https://curecurrent.com/trials/global-regional-and-national-burdens-and-trends-of-tracheal-bronchial-and-lung-cancer-in-individuals-aged-70-years-and-o-46141https://curecurrent.com/trials/real-world-observational-study-of-targeted-therapy-in-patients-with-advanced-ros1-positive-nsclc-46142https://curecurrent.com/trials/propranolol-hydrochloride-in-combination-with-sintilimab-and-platinum-based-chemotherapy-for-treatment-of-advanced-non-s-46143https://curecurrent.com/trials/neoadjuvant-toripalimab-for-clinically-stage-ii-iiib-resectable-non-small-cell-lung-cancer-with-egfr-mutation-and-pd-l1-46144https://curecurrent.com/trials/evaluation-of-clinical-performance-and-ivd-test-of-lifeos-digital-pcr-liquid-biopsy-kits-for-egfr-t790m-mutation-46145https://curecurrent.com/trials/transthoracic-shear-wave-ultrasound-elastography-46146https://curecurrent.com/trials/oral-tead-inhibitor-targeting-the-hippo-pathway-in-subjects-with-advanced-solid-tumors-46147https://curecurrent.com/trials/deprecap-lung-cancer-screening-programme-by-ldct-for-patients-with-copd-or-emphysema-46148https://curecurrent.com/trials/a-phase-1-2a-study-of-23me-00610-in-patients-with-advanced-solid-malignancies-46149https://curecurrent.com/trials/real-world-study-of-local-therapy-changes-during-1l-lorlatinib-in-unresectable-alk-nsclc-46150https://curecurrent.com/trials/a-single-arm-phase-b-study-of-golidocitinib-combined-with-anti-pd-1-for-the-treatment-of-previously-treated-nsclc-46151https://curecurrent.com/trials/a-prospective-study-frailty-for-esophagectomy-and-lung-resection-in-thoracic-surgery-46152https://curecurrent.com/trials/an-open-study-of-asp8273-in-patients-with-non-small-cell-lung-cancer-nsclc-who-have-epidermal-growth-factor-receptor-egf-46153https://curecurrent.com/trials/a-dose-escalation-study-of-asp8273-in-subjects-with-non-small-cell-lung-cancer-nsclc-who-have-epidermal-growth-factor-re-46154https://curecurrent.com/trials/incorporating-veterans-preferences-into-lung-cancer-screening-decisions-46155https://curecurrent.com/trials/flower-following-longitudinal-outcomes-with-epidemiology-for-rare-diseases-46156https://curecurrent.com/trials/dream-double-lung-transplant-registry-aimed-for-lung-limited-malignancies-46157https://curecurrent.com/trials/neoadjuvant-chemotherapy-sequentially-combined-with-sintilimab-in-resectable-egfr-mutant-nsclc-46158https://curecurrent.com/trials/perioperative-treatment-outcomes-of-early-nsclc-46159https://curecurrent.com/trials/study-of-gsk3901961-in-previously-treated-advanced-metastatic-or-unresectable-synovial-sarcoma-myxoid-round-cell-liposar-46160https://curecurrent.com/trials/clinical-utility-of-management-of-patients-with-pulmonary-nodules-using-the-percepta-nasal-swab-classifier-46161https://curecurrent.com/trials/study-to-evaluate-the-safety-and-efficacy-of-serplulimab-plus-bevacizumab-and-chemotherapy-in-nsclc-patients-with-brain-46162https://curecurrent.com/trials/ai-guided-prognostication-and-cranial-radiotherapy-optimization-in-egfr-tki-treated-non-small-cell-lung-cancer-patients-46163https://curecurrent.com/trials/managed-access-program-cohort-treatment-plan-ctmt212x2002i-to-provide-access-to-trametinib-and-dabrafenib-combination-th-46164https://curecurrent.com/trials/carboplatin-and-paclitaxel-with-or-without-vorinostat-in-treating-patients-with-advanced-non-small-cell-lung-cancer-46165https://curecurrent.com/trials/personalized-neoantigen-mrna-vaccine-combined-with-adebrelimab-in-non-small-cell-lung-cancer-patients-46166https://curecurrent.com/trials/lorlatinib-as-neoadjuvant-treatment-in-stage-ib-iiib-alk-rearranged-non-small-cell-lung-cancer-46167https://curecurrent.com/trials/til-therapy-combined-with-pembrolizumab-for-advanced-or-metastatic-refractory-stomach-and-esophageal-cancer-46168https://curecurrent.com/trials/constructing-a-predictive-model-for-differentiating-between-benign-and-malignant-solid-pulmonary-nodules-based-on-clinic-46169https://curecurrent.com/trials/oral-cell-dna-adducts-in-smokers-46170https://curecurrent.com/trials/a-study-of-shr-a2102-in-combination-with-adebrelimab-and-shr-8068-in-subjects-with-locally-advanced-or-metastatic-non-sm-46171https://curecurrent.com/trials/utidelone-injection-combined-with-bevacizumab-injection-for-non-small-cell-lung-cancer-patients-with-brain-metastases-46172https://curecurrent.com/trials/a-study-evaluating-safety-and-therapeutic-activity-of-anv419-in-patients-with-advanced-cancer-46173https://curecurrent.com/trials/long-term-safety-observation-of-crizotinib-in-chinese-nsclc-population-46174https://curecurrent.com/trials/bio-11006-for-osteosarcoma-and-ewing-s-sarcoma-lung-metastases-46175https://curecurrent.com/trials/influence-of-a-home-based-nutrition-and-exercise-program-on-quality-of-life-of-palliative-cancer-outpatients-46176https://curecurrent.com/trials/a-study-to-evaluate-pegsitacianine-an-intraoperative-fluorescence-imaging-agent-for-the-detection-of-lung-malignancies-46177https://curecurrent.com/trials/study-to-access-safety-of-durvalumab-in-indian-adult-patients-with-locally-advanced-nsclc-46178https://curecurrent.com/trials/transbroncheal-novel-pdt-peripheral-lung-tumor-ablation-with-5-ala-46179https://curecurrent.com/trials/almonertinib-versus-placebo-as-adjuvant-therapy-in-resected-stage-ii-iiib-non-small-cell-lung-cancer-with-egfr-sensitive-46180https://curecurrent.com/trials/prelude-1-prospective-evaluation-of-radiotherapy-induced-biologic-effects-in-colorectal-cancer-oligometastatic-patients-46181https://curecurrent.com/trials/teipp-immunotherapy-in-patients-with-nsclc-46182https://curecurrent.com/trials/determination-of-peripheral-immune-cell-activity-during-treatment-with-either-surgery-or-radiotherapy-in-patients-with-e-46183https://curecurrent.com/trials/atezolizumab-combined-with-chemotherapy-in-extensive-stage-sclc-46184https://curecurrent.com/trials/ici-rechallenge-for-advanced-nsclc-with-long-term-response-to-first-line-ici-46185https://curecurrent.com/trials/phase-1-dose-escalation-and-expansion-to-evaluate-arog4-01-in-patients-with-advanced-solid-tumors-46186https://curecurrent.com/trials/a-study-in-advanced-metastatic-solid-tumors-with-the-study-medicine-pf-07329640-when-given-alone-or-in-combination-46187https://curecurrent.com/trials/phase-ii-azd9291-open-label-study-in-nsclc-after-previous-egfr-tki-therapy-in-egfr-and-t790m-mutation-positive-tumours-46188https://curecurrent.com/trials/assess-the-safety-of-immunotherapy-induction-with-tremelimumab-and-durvalumab-prior-to-chemoradiotherapy-and-or-resectio-46189https://curecurrent.com/trials/pembrolizumab-plus-lenvatinib-in-second-line-and-third-line-malignant-pleural-mesothelioma-patients-46190https://curecurrent.com/trials/functional-lung-imaging-with-dect-and-4dct-46191https://curecurrent.com/trials/activity-of-lorlatinib-based-on-alk-resistance-mutations-detected-on-blood-in-alk-positive-nsclc-patients-46192https://curecurrent.com/trials/furmonertinib-160mg-as-first-line-treatment-in-locally-advanced-or-metastatic-nsclc-with-egfr-classical-mutations-46193https://curecurrent.com/trials/study-of-mt-6402-in-subjects-with-advanced-solid-cancer-that-expresses-pd-l1-46194https://curecurrent.com/trials/clinical-performance-study-protocol-for-therascreen-kras-rgq-pcr-kit-46195https://curecurrent.com/trials/lung-screening-in-people-cured-of-hodgkin-lymphoma-46196https://curecurrent.com/trials/clinical-study-testing-dna-extracted-from-tumour-tissue-biopsy-samples-using-the-therascreen-kras-rgq-pcr-kit-46197https://curecurrent.com/trials/phase-1-2-study-of-hs-10375-in-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc-46198https://curecurrent.com/trials/testing-of-dna-extracted-from-tumor-tissue-biopsy-samples-using-therascreen-kras-rgq-pcr-kit-46199https://curecurrent.com/trials/study-of-mt-8421-as-monotherapy-and-in-combination-with-nivolumab-in-patients-with-selected-advanced-solid-cancer-types-46200https://curecurrent.com/trials/efficacy-analysis-of-neoadjuvant-treatment-in-lung-cancer-using-low-dose-nivolumab-combined-with-chemotherapy-46201https://curecurrent.com/trials/sodium-glycididazole-reduces-the-adverse-reactions-of-concurrent-chemoradiotherapy-46202https://curecurrent.com/trials/testing-a-cognitive-behavioral-model-for-reducing-dyspnea-in-patients-with-lung-cancer-46203https://curecurrent.com/trials/a-phase-3-controlled-open-label-global-randomized-study-of-rrx-001-with-a-platinum-doublet-or-a-platinum-doublet-in-smal-46204https://curecurrent.com/trials/a-study-to-compare-ociperlimab-plus-tislelizumab-versus-durvalumab-following-concurrent-chemoradiotherapy-ccrt-in-partic-46205https://curecurrent.com/trials/study-of-osimertinib-srs-vs-osimertinib-alone-for-brain-metastases-in-egfr-positive-patients-with-nsclc-46206https://curecurrent.com/trials/study-of-tislelizumab-for-locally-advanced-non-small-cell-lung-cancer-following-neoadjuvant-chemotherapy-plus-tislelizum-46207https://curecurrent.com/trials/vertebral-marrow-attention-trial-vmat-46208https://curecurrent.com/trials/ldct-screening-in-non-smokers-in-taiwan-46209https://curecurrent.com/trials/vinorelbine-and-bevacizumab-in-treating-older-patients-with-stage-iii-or-stage-iv-non-small-cell-lung-cancer-46210https://curecurrent.com/trials/feasibility-study-of-anatomical-modeling-for-image-guided-thoracic-surgery-46211https://curecurrent.com/trials/assessing-the-integration-of-tobacco-cessation-treatment-into-lung-cancer-screening-lcs-46212https://curecurrent.com/trials/a-study-of-tislelizumab-in-combination-with-chemotherapy-versus-chemotherapy-in-advanced-lung-cancer-46213https://curecurrent.com/trials/effect-of-ultrasound-positioning-assisted-cheek-needle-therapy-on-postoperative-recovery-quality-of-patients-with-radica-46214https://curecurrent.com/trials/circulating-tumor-dna-alterations-in-non-small-cell-lung-cancer-patients-treated-with-pembrolizumab-46215https://curecurrent.com/trials/intra-pleural-administration-of-gl-onc1-a-genetically-modified-vaccinia-virus-in-patients-with-malignant-pleural-effusio-46216https://curecurrent.com/trials/deep-learning-model-to-predict-the-recurrence-of-stage-ia-invasive-lung-adenocarcinoma-after-sub-lobar-resection-46217https://curecurrent.com/trials/study-of-ociperlimab-plus-tislelizumab-plus-chemoradiotherapy-in-participants-with-untreated-limited-stage-small-cell-lu-46218https://curecurrent.com/trials/imaging-advanced-nsclc-patients-undergoing-pd-1-pd-l1-directed-therapy-using-18f-farag-46219https://curecurrent.com/trials/bt1718-in-patients-with-advanced-solid-tumours-46220https://curecurrent.com/trials/test-retest-evaluation-of-18f-f-arag-pet-46221https://curecurrent.com/trials/surgery-and-or-radiation-therapy-or-standard-therapy-and-or-clinical-observation-in-treating-patients-with-previously-tr-46222https://curecurrent.com/trials/study-of-liposomal-annamycin-for-the-treatment-of-subjects-with-soft-tissue-sarcomas-sts-with-pulmonary-metastases-46223https://curecurrent.com/trials/a-study-of-atezolizumab-compared-with-a-single-agent-chemotherapy-in-treatment-na-ve-participants-with-locally-advanced-46224https://curecurrent.com/trials/pembrolizumab-in-elderly-patients-with-advanced-lung-cancer-46225https://curecurrent.com/trials/pembrolizumab-with-and-without-radiotherapy-for-non-small-cell-lung-cancer-46226https://curecurrent.com/trials/robotic-bronchoscopy-with-cone-ct-and-indocyanine-green-to-aid-removal-of-lung-lesions-in-patients-with-stage-i-non-smal-46227https://curecurrent.com/trials/anti-pd-1-in-combination-with-chemotherapy-as-first-line-treatment-to-lung-cancer-46228https://curecurrent.com/trials/alvopem-pemetrexed-safety-assessment-46229https://curecurrent.com/trials/study-of-inbrx-105-and-inbrx-105-with-pembrolizumab-in-patients-with-solid-tumors-including-head-and-neck-cancer-46230https://curecurrent.com/trials/the-incidence-and-risk-factors-of-central-nervous-system-adverse-events-of-lorlatinib-in-patients-with-alk-positive-adva-46231https://curecurrent.com/trials/osimertinib-then-chemotherapy-in-egfr-mutated-lung-cancer-with-osimertinib-third-line-rechallenge-46232https://curecurrent.com/trials/development-and-demonstration-of-intelligent-assessment-based-on-multi-modal-information-fusion-for-tumor-risk-and-diagn-46233https://curecurrent.com/trials/treatment-strategies-and-survival-outcome-for-non-small-cell-lung-cancer-with-oncogenic-mutation-46234https://curecurrent.com/trials/combination-rucaparib-with-nivolumab-in-small-cell-lung-carcinoma-46235https://curecurrent.com/trials/imaging-study-on-halcyon-4-0-system-for-patients-receiving-radiation-therapy-46236https://curecurrent.com/trials/wsi-based-dl-for-diagnosing-the-iaslc-grading-system-of-lung-adenocarcinoma-46237https://curecurrent.com/trials/advancing-lung-cancer-screening-artificial-intelligence-multimodal-imaging-and-cutting-edge-technologies-for-early-detec-46238https://curecurrent.com/trials/a-molecular-profiling-study-of-patients-with-egfr-mutation-positive-locally-advanced-or-metastatic-nsclc-treated-with-os-46239https://curecurrent.com/trials/artificial-intelligence-based-voice-assessment-of-children-and-adults-respiratory-conditions-46240https://curecurrent.com/trials/adebrelimab-combined-with-irinotecan-liposomes-5-fu-cf-lenvatinib-as-first-line-treatment-for-advanced-icc-46241https://curecurrent.com/trials/neoadjuvant-pd-1-inhibitor-sintilimab-anlotinib-combined-with-chemotherapy-in-resectable-stage-iia-iiib-nsclc-46242https://curecurrent.com/trials/fdg-pet-ct-radiomics-analyses-of-lung-cancer-patients-treated-with-immunotherapy-46243https://curecurrent.com/trials/prevalence-and-risk-factors-of-pulmonary-hypertension-in-patients-with-myeloproliferative-neoplasms-in-assiut-university-46244https://curecurrent.com/trials/toripalimab-and-js004-combined-with-platinum-based-chemotherapy-for-relapsed-and-extensive-stage-small-cell-lung-cancer-46245https://curecurrent.com/trials/split-course-adaptive-radiation-therapy-with-pembrolizumab-with-without-chemotherapy-for-treating-stage-iv-lung-cancer-46246https://curecurrent.com/trials/retrospective-analysis-of-clinical-and-ct-features-to-predict-spread-through-air-space-in-stage-ia-lung-adenocarcinoma-46247https://curecurrent.com/trials/phase-2-study-of-vgt-309-in-lung-cancer-46248https://curecurrent.com/trials/segmentectomy-versus-lobectomy-in-t1c-non-small-cell-lung-cancer-seltic-46249https://curecurrent.com/trials/artemis-008-hs-20093-compared-with-topotecan-in-subjects-with-relapsed-small-cell-lung-cancer-46250https://curecurrent.com/trials/vebreltinib-for-neoadjuvant-in-met-altered-stage-iiia-iiib-n2-non-small-cell-lung-cancer-nsclc-46251https://curecurrent.com/trials/impact-of-telemonitoring-for-the-management-of-side-effects-in-patients-with-melanoma-lung-or-renal-cancer-treated-with-46252https://curecurrent.com/trials/antirotinib-hydrochloride-plus-whole-brain-radiotherapy-for-small-cell-lung-cancer-with-brain-metastases-46253https://curecurrent.com/trials/a-study-on-the-safety-and-efficacy-of-bst08-in-treating-advanced-non-small-cell-lung-cancer-46254https://curecurrent.com/trials/pembrolizumab-and-afatinib-in-patients-with-non-small-cell-lung-cancer-with-resistance-to-erlotinib-46255https://curecurrent.com/trials/shared-decision-making-in-rural-primary-care-lung-cancer-screening-and-smoking-cessation-46256https://curecurrent.com/trials/identification-of-prognostic-and-predictive-biomarkers-of-toxicity-in-patients-with-malignant-pleural-mesothelioma-and-t-46257https://curecurrent.com/trials/comparison-of-sublobar-and-lobectomy-in-small-2-cm-or-less-0-5-ctr-1-non-small-cell-lung-cancer-a-prospective-multicente-46258https://curecurrent.com/trials/improving-utilization-of-lung-cancer-screening-in-underserved-pa-populations-46259https://curecurrent.com/trials/a-study-of-ql1706-combined-with-platinum-containing-chemotherapy-in-adjuvant-treatment-of-stage-ii-iiib-non-small-cell-l-46260https://curecurrent.com/trials/assessment-of-novel-biomarkers-in-participants-undergoing-targeted-lung-health-checks-46261https://curecurrent.com/trials/study-of-pemetrexed-plus-cisplatin-as-first-line-therapy-in-patients-with-advanced-non-squamous-nsclc-46262https://curecurrent.com/trials/study-to-evaluate-d-1553-in-subjects-with-lung-cancer-46263https://curecurrent.com/trials/impact-of-the-covid-19-pandemic-on-oncologic-outcomes-in-colorectal-cancer-46264https://curecurrent.com/trials/use-of-integrated-pulmonary-index-monitorisation-in-children-undergoing-botulinum-toxin-injection-46265https://curecurrent.com/trials/a-study-to-evaluate-d-1553-in-combination-therapy-in-non-small-cell-lung-cancer-46266https://curecurrent.com/trials/tc99m-maa-bronchial-artery-injection-during-bronchial-embolization-for-pulmonary-mass-induced-hemoptysis-for-dosimetry-p-46267https://curecurrent.com/trials/auto-hsct-supported-dose-dense-chemotherapy-with-adebrelimab-as-first-line-treatment-for-es-sclc-46268https://curecurrent.com/trials/developing-optimal-parameters-for-hyperpolarized-noble-gas-and-inert-fluorinated-gas-mri-of-lung-disorders-46269https://curecurrent.com/trials/til-therapy-combined-with-pembrolizumab-for-advanced-or-metastatic-refractory-lung-cancer-46270https://curecurrent.com/trials/safety-and-efficacy-of-cryoablation-with-karelizumab-and-apatinib-for-multiple-lung-cancers-46271https://curecurrent.com/trials/safety-of-effivia-a-bevacizumab-biosimilar-46272https://curecurrent.com/trials/study-to-test-the-safety-and-how-radium-223-dichloride-an-alpha-particle-emitting-radioactive-agent-works-in-combination-46273https://curecurrent.com/trials/ds-3201b-and-irinotecan-for-patients-with-recurrent-small-cell-lung-cancer-46274https://curecurrent.com/trials/third-generation-egfr-tki-plus-anlotinib-as-maintenance-for-nsclc-with-small-cell-transformation-after-egfr-tki-resistan-46275https://curecurrent.com/trials/segmentectomy-for-solid-dominant-lung-cancer-46276https://curecurrent.com/trials/safety-and-efficacy-of-capmatinib-inc280-plus-pembrolizumab-vs-pembrolizumab-alone-in-nsclc-with-pd-l1-50-46277https://curecurrent.com/trials/lung-cancer-screening-navigation-for-homeless-people-46278https://curecurrent.com/trials/galinpepimut-s-wt-1-analog-peptide-vaccine-in-malignant-pleural-mesothelioma-after-combined-modality-therapy-46279https://curecurrent.com/trials/an-international-randomized-trial-of-additional-treatments-for-covid-19-in-hospitalized-patients-who-are-all-receiving-t-46280https://curecurrent.com/trials/study-of-capmatinib-and-spartalizumab-placebo-in-advanced-nsclc-patients-with-met-exon-14-skipping-mutations-46281https://curecurrent.com/trials/pembrolizumab-in-patients-with-metastatic-non-squamous-non-small-cell-lung-cancer-46282https://curecurrent.com/trials/atezolizumab-in-combination-with-carboplatin-plus-pemetrexed-in-chemotherapy-na-ve-patients-with-asymptomatic-brain-meta-46283https://curecurrent.com/trials/brief-title-study-of-efficacy-and-safety-of-canakinumab-as-adjuvant-therapy-in-adult-subjects-with-stages-ajcc-uicc-v-8-46284https://curecurrent.com/trials/phase-i-ii-eval-safety-prelim-activity-nivolumab-comb-w-vorolanib-pts-w-refractory-thoracic-tumors-46285https://curecurrent.com/trials/brigatinib-post-definitive-chemo-radiotherapy-in-patients-with-alk-fusion-non-small-cell-lung-cancer-46286https://curecurrent.com/trials/promoting-smoking-cessation-in-lung-cancer-screening-through-proactive-treatment-46287https://curecurrent.com/trials/a-study-of-carboplatin-paclitaxel-nab-paclitaxel-chemotherapy-with-or-without-pembrolizumab-mk-3475-in-adults-with-first-46288https://curecurrent.com/trials/durvalumab-alone-or-in-combination-with-novel-agents-in-subjects-with-nsclc-46289https://curecurrent.com/trials/multi-disciplinary-treatment-on-the-anthropomorphism-of-large-language-models-46290https://curecurrent.com/trials/investigating-the-feasibility-of-a-physical-activity-tele-coaching-intervention-in-patients-with-non-small-cell-lung-can-46291https://curecurrent.com/trials/stereotactic-body-radiation-therapy-for-inoperable-locally-advanced-non-small-cell-lung-cancer-46292https://curecurrent.com/trials/improving-detection-of-early-lung-cancer-in-a-diverse-population-ideal-study-46293https://curecurrent.com/trials/development-of-an-artificial-intelligence-model-for-the-identification-and-prevention-of-smoking-related-diseases-46294https://curecurrent.com/trials/cmr-right-ventricular-contractile-reserve-following-lung-resection-46295https://curecurrent.com/trials/b-cell-hematologic-malignancy-vaccination-registry-46296https://curecurrent.com/trials/study-of-the-immune-response-after-vaccination-in-multiple-myeloma-patients-46297https://curecurrent.com/trials/microplastics-in-the-human-respiratory-system-46298https://curecurrent.com/trials/cancer-patient-remote-monitoring-for-timely-communication-study-46299https://curecurrent.com/trials/the-application-value-of-68ga-grazytracer-pet-in-immunotherapy-for-stage-iii-non-small-cell-lung-cancer-46300https://curecurrent.com/trials/camrelizumab-plus-famitinib-as-treatment-in-patient-with-advanced-or-metastatic-pulmonary-sarcomatoid-carcinoma-46301https://curecurrent.com/trials/molecular-profiling-and-targeted-therapy-for-advanced-non-small-cell-lung-cancer-small-cell-lung-cancer-and-thymic-malig-46302https://curecurrent.com/trials/tp53-r248q-tcr-t-cell-therapy-for-advanced-solid-tumor-46303https://curecurrent.com/trials/local-injection-and-systemic-therapy-in-the-treatment-of-nsclc-46304https://curecurrent.com/trials/a-bridging-study-of-pf-06439535-cn-plus-paclitaxel-carboplatin-versus-bevacizumab-plus-paclitaxel-carboplatin-in-nsclc-46305https://curecurrent.com/trials/a-first-in-human-study-to-evaluate-the-safety-and-tolerability-of-azd8853-in-participants-with-selected-advanced-metasta-46306https://curecurrent.com/trials/pembrolizumab-plus-autologous-dendritic-cell-vaccine-in-patients-with-pd-l1-negative-advanced-mesothelioma-who-have-fail-46307https://curecurrent.com/trials/clinico-immunological-characterization-and-immune-tolerance-breakdown-in-cv2-autoimmunity-46308https://curecurrent.com/trials/a-phase-ii-study-of-ivonescimab-combined-with-cadonilimab-and-chemotherapy-in-extensive-stage-small-cell-lung-cancer-46309https://curecurrent.com/trials/application-of-machine-learning-algorithms-to-identify-optimal-candidates-for-primary-tumor-resection-in-patients-with-m-46310https://curecurrent.com/trials/a-study-of-carboplatin-paclitaxel-nab-paclitaxel-chemotherapy-with-or-without-pembrolizumab-mk-3475-in-adults-with-first-46311https://curecurrent.com/trials/real-time-optical-biopsy-in-improving-lung-cancer-diagnosis-in-patients-undergoing-lung-biopsy-46312https://curecurrent.com/trials/efficacy-of-pd-1-inhibitor-combination-therapy-in-non-small-cell-lung-cancer-patients-who-have-not-achieved-major-pathol-46313https://curecurrent.com/trials/an-investigational-scan-124i-hjaa-f11-pet-ct-for-diagnosing-lung-cancer-46314https://curecurrent.com/trials/advance-care-planning-impact-on-the-consistency-of-older-adults-with-lung-cancer-and-their-potential-surrogates-regardin-46315https://curecurrent.com/trials/descriptive-observational-study-alk-2016-cphg-46316https://curecurrent.com/trials/pet-guided-radiotherapy-for-patients-with-small-cell-lung-cancer-46317https://curecurrent.com/trials/bomedemstat-and-maintenance-immunotherapy-for-treatment-of-newly-diagnosed-extensive-stage-small-cell-lung-cancer-46318https://curecurrent.com/trials/a-study-of-adebelimab-combined-with-chemotherapy-as-a-first-line-treatment-sequential-treatment-for-extensive-stage-smal-46319https://curecurrent.com/trials/neoajuvant-tislelizumab-combined-with-chemotherapy-for-initially-unresectable-stage-iiia-n2-non-small-cell-lung-cancer-46320https://curecurrent.com/trials/berzosertib-topotecan-in-relapsed-platinum-resistant-small-cell-lung-cancer-ddriver-sclc-250-46321https://curecurrent.com/trials/microbiota-transplant-in-advanced-lung-cancer-treated-with-immunotherapy-46322https://curecurrent.com/trials/icotinib-for-completed-resected-ib-nsclc-with-egfr-mutation-46323https://curecurrent.com/trials/association-between-microbiome-and-the-efficacy-and-safety-of-pd-1-pd-l1-blockade-in-resectable-nsclc-46324https://curecurrent.com/trials/a-first-in-human-study-of-jab-3068-shp2-inhibitor-in-adult-patients-with-advanced-solid-tumors-in-china-46325https://curecurrent.com/trials/efficacy-and-safety-of-intratumoral-toluenesulfonamide-pts-injection-in-stage-iv-driver-gene-negative-nsclc-with-without-46326https://curecurrent.com/trials/lifei-xiaoji-wan-in-treatment-of-advanced-nsclc-46327https://curecurrent.com/trials/quilt-2-017-phase-1b-2-study-of-amg-479-in-combination-with-paclitaxel-and-carboplatin-for-1st-line-treatment-of-advance-46328https://curecurrent.com/trials/a-study-of-kf-0210-in-advanced-solid-tumors-patients-46329https://curecurrent.com/trials/trilaciclib-prevents-myelosuppression-with-chemoradiotherapy-46330https://curecurrent.com/trials/multi-omics-analysis-to-characterize-the-invasive-evolution-of-pulmonary-subsolid-nodules-46331https://curecurrent.com/trials/mondrian-multi-omics-integrative-modelling-for-stereotactic-body-radiotherapy-in-early-stage-non-small-cell-lung-cancer-46332https://curecurrent.com/trials/neoadjuvant-with-t-1-plus-immuno-chemotherapy-for-resectable-nsclc-46333https://curecurrent.com/trials/sequential-chemo-immunotherapy-plus-thoracic-radiotherapy-for-elderly-and-or-frail-stage-iii-non-small-cell-lung-cancer-46334https://curecurrent.com/trials/68ga-grazytracer-pet-assists-in-diagnosing-pseudoprogression-following-immunotherapy-in-lung-cancer-46335https://curecurrent.com/trials/care-initiative-real-world-emulation-of-the-keynote-189-trial-ds3-46336https://curecurrent.com/trials/the-thoracic-peri-operative-integrative-surgical-care-evaluation-poise-trial-stage-i-46337https://curecurrent.com/trials/study-of-pemetrexed-platinum-chemotherapy-with-or-without-pembrolizumab-mk-3475-in-participants-with-first-line-metastat-46338https://curecurrent.com/trials/alk-tyrosine-kinase-inhibitors-in-alk-rearranged-advanced-squamous-cell-carcinoma-46339https://curecurrent.com/trials/docetaxel-carboplatin-as-second-line-treatment-in-patients-with-small-cell-lung-cancer-46340https://curecurrent.com/trials/a-study-with-central-nervous-system-metastatic-egfr-mutation-positive-non-small-cell-lung-cancer-46341https://curecurrent.com/trials/sunvozertinib-plus-anlotinib-as-1l-treatment-in-egfr-mutant-advanced-nsclc-rw-46342https://curecurrent.com/trials/immunogenicity-and-safety-of-pneumococcal-vaccination-in-patients-treated-with-immune-checkpoint-inhibitors-46343https://curecurrent.com/trials/intrathecal-pemetrexed-combined-with-high-dose-furmonertinib-and-beva-for-egfr-m-nsclc-with-leptomeningeal-metastases-46344https://curecurrent.com/trials/a-real-world-study-of-treatment-patterns-and-effectiveness-in-met-mutation-positive-advanced-lung-cancer-46345https://curecurrent.com/trials/js-201-combined-with-lenvatinib-in-the-treatment-of-small-cell-lung-cancer-46346https://curecurrent.com/trials/sunvozertinib-plus-anlotinib-as-1l-treatment-in-egfr-sensitive-mutations-combined-with-co-mutations-advanced-nsclc-46347https://curecurrent.com/trials/the-short-term-impact-of-vocal-intonation-therapy-vit-and-therapeutic-singing-ts-on-respiratory-function-in-patients-wit-46348https://curecurrent.com/trials/rssearch-patient-registry-long-term-study-of-use-of-srs-sbrt-46349https://curecurrent.com/trials/the-development-and-study-of-a-3d-printed-model-for-surgical-planning-of-lung-cancer-with-realistic-subsegmental-boundar-46350https://curecurrent.com/trials/improving-the-intraoperative-diagnosis-accuracy-of-invasiveness-for-small-sized-lung-adenocarcinoma-46351https://curecurrent.com/trials/jab-3068-activity-in-adult-patients-with-advanced-solid-tumors-46352https://curecurrent.com/trials/high-dose-furmonertinib-for-first-line-treatment-of-egfr-mutated-nsclc-with-central-nervous-system-cns-metastases-46353https://curecurrent.com/trials/chemotherapy-combined-with-immunotherapy-in-her-2-insertion-or-amplification-advanced-nsclc-46354https://curecurrent.com/trials/induction-therapy-with-serplulimab-combined-with-chemotherapy-for-unresectable-stage-iii-non-small-cell-lung-cancer-46355https://curecurrent.com/trials/the-effect-of-a-mobile-application-on-enhancing-pulmonary-rehabilitation-after-lung-cancer-surgery-46356https://curecurrent.com/trials/study-of-mogamulizumab-docetaxel-in-subjects-with-non-small-cell-lung-cancer-46357https://curecurrent.com/trials/the-effects-of-programmed-death-ligand-1-on-postoperative-pain-for-lung-cancer-patients-46358https://curecurrent.com/trials/the-impact-of-communication-with-healthcare-providers-via-wechat-on-survival-outcomes-for-lung-cancer-patietns-46359https://curecurrent.com/trials/safety-and-efficacy-study-of-nab-paclitaxel-with-cc-486-or-nab-paclitaxel-with-durvalumab-and-nab-paclitaxel-monotherapy-46360https://curecurrent.com/trials/ph009-1-in-patients-with-egfr-mutation-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc-46361https://curecurrent.com/trials/a-study-of-atezolizumab-as-neoadjuvant-and-adjuvant-therapy-in-resectable-non-small-cell-lung-cancer-nsclc-lung-cancer-m-46362https://curecurrent.com/trials/harnessing-allo-immunity-to-enhance-immune-checkpoint-inhibitor-responses-in-advanced-nsclc-46363https://curecurrent.com/trials/atezolizumab-combined-with-platinum-based-chemotherapy-as-neoadjuvant-therapy-for-patients-with-resectable-stage-ii-iiib-46364https://curecurrent.com/trials/immuno-effect-of-t-1-for-stage-i-nsclc-46365https://curecurrent.com/trials/phase-ii-clinical-trial-to-evaluate-the-safety-and-efficacy-of-tqb2450-injection-combined-with-anlotinib-capsule-and-che-46366https://curecurrent.com/trials/study-of-pembrolizumab-versus-docetaxel-in-participants-previously-treated-for-non-small-cell-lung-cancer-mk-3475-033-ke-46367https://curecurrent.com/trials/a-randomized-phase-2-trial-of-tas-114-in-combination-with-s-1-versus-s-1-46368https://curecurrent.com/trials/using-circulating-tumor-dna-to-personalize-duration-of-consolidation-durvalumab-46369https://curecurrent.com/trials/the-patient-reported-outcomes-in-alk-positive-advanced-nsclc-in-china-46370https://curecurrent.com/trials/study-of-azd9291-plus-medi4736-versus-azd9291-monotherapy-in-nsclc-after-previous-egfr-tki-therapy-in-t790m-mutation-pos-46371https://curecurrent.com/trials/a-novel-lung-function-imaging-modality-as-a-preoperative-evaluation-tool-lime-46372https://curecurrent.com/trials/first-line-treatment-for-es-sclc-with-chemotherapy-combined-with-pd-1-pd-l1-inhibitor-sequential-thoracic-radiotherapy-46373https://curecurrent.com/trials/intrathecal-pemetrexed-for-sclc-patients-with-refractory-brain-metastases-or-leptomeninges-metastatic-46374https://curecurrent.com/trials/reinforced-and-non-reinforced-staple-lines-in-fissureless-lobectomy-46375https://curecurrent.com/trials/imp4297-in-combination-with-temozolomide-in-patients-with-advanced-solid-tumors-and-small-cell-lung-cancer-46376https://curecurrent.com/trials/hypofractionated-radiotherapy-combined-with-immunotherapy-for-limited-stage-small-cell-lung-cancer-46377https://curecurrent.com/trials/sintilimab-after-radiation-star-study-46378https://curecurrent.com/trials/the-effects-of-an-nutritional-intervention-on-pd-1-ici-in-nsclc-46379https://curecurrent.com/trials/re-induction-of-a-systemic-immune-response-in-metastatic-or-locally-recurrent-lung-cancer-46380https://curecurrent.com/trials/implementation-of-up-front-ctdna-into-lung-cancer-care-and-development-of-liquid-biopsy-based-decision-support-models-lm-46381https://curecurrent.com/trials/pembrolizumab-combined-with-double-platinum-based-chemotherapy-for-potentially-resectable-nsclc-46382https://curecurrent.com/trials/induction-therapy-with-pd-1-antibody-combined-with-platinum-based-doublet-chemotherapy-for-locally-advanced-non-small-ce-46383https://curecurrent.com/trials/a-retrospective-study-evaluation-of-the-efficacy-of-immunotherapy-with-rare-mutations-in-non-small-cell-lung-cancer-46384https://curecurrent.com/trials/radiotherapy-to-the-primary-in-metastatic-non-small-cell-lung-cancer-patients-46385https://curecurrent.com/trials/a-phase-ib-study-of-hs-10370-in-addition-to-other-anti-cancer-therapies-in-participants-with-kras-g12c-mutation-advanced-46386https://curecurrent.com/trials/anaplastic-lymphoma-kinase-alk-positive-non-small-cell-lung-cancer-nsclc-post-alectinib-treatment-patterns-46387https://curecurrent.com/trials/distress-associated-with-coronavirus-disease-2019-and-telehealth-on-supportive-care-patients-with-advanced-cancer-46388https://curecurrent.com/trials/pd-1-combined-with-pyrotinib-for-chemotherapy-failure-her2-insertion-mutation-advanced-nsclc-46389https://curecurrent.com/trials/phase-1b-2-study-of-futibatinib-in-combination-with-binimetinib-in-patients-with-advanced-kras-mutant-cancer-46390https://curecurrent.com/trials/bronchoscopic-cryoablation-combined-with-chemo-immunotherapy-in-nsclc-with-central-airway-obstruction-46391https://curecurrent.com/trials/real-world-effectiveness-of-afatinib-gilotrif-following-immunotherapy-in-the-treatment-of-metastatic-squamous-cell-carci-46392https://curecurrent.com/trials/clinical-trial-of-tqb2928-in-combination-with-a-third-generation-epidermal-growth-factor-receptor-egfr-tyrosine-kinase-i-46393https://curecurrent.com/trials/a-clinical-trial-of-furmonertinib-combination-therapy-as-neoadjuvant-treatment-in-resectable-egfr-mutated-nsclc-46394https://curecurrent.com/trials/icotinib-following-chemotherapy-versus-chemotherapy-as-adjuvant-therapy-in-stage-iia-iiia-nsclc-with-egfr-mutation-46395https://curecurrent.com/trials/a-phase-2-study-comparing-tas-102-versus-topotecan-or-amrubicin-to-treat-small-cell-lung-cancer-following-platinum-based-46396https://curecurrent.com/trials/care-initiative-real-world-emulation-of-the-keynote-189-trial-ds4-46397https://curecurrent.com/trials/efficacy-and-safety-of-almonertinib-combined-with-stereotactic-body-radiotherapy-sbrt-in-the-treatment-of-non-small-cell-46398https://curecurrent.com/trials/trial-of-bms-986012-in-combination-with-platinum-and-etoposide-46399https://curecurrent.com/trials/ctdna-dynamic-monitoring-and-its-role-of-prognosis-in-stage-i-nscls-by-ngs-46400https://curecurrent.com/trials/combination-treatment-talazoparib-plus-avelumab-for-stage-iv-or-recurrent-non-squamous-non-small-cell-lung-cancer-with-s-46401https://curecurrent.com/trials/validate-the-safety-and-feasibility-of-the-ct-guided-interventional-robot-in-percutaneous-lung-cryablation-procedures-46402https://curecurrent.com/trials/ramucirumab-and-pembrolizumab-versus-standard-of-care-in-treating-patients-with-stage-iv-or-recurrent-non-small-cell-lun-46403https://curecurrent.com/trials/phase-2-study-of-s-1-in-combination-with-cisplatin-as-1st-line-therapy-in-advanced-non-small-cell-lung-cancer-46404https://curecurrent.com/trials/a-pilot-study-of-response-driven-adaptive-radiation-therapy-for-patients-with-locally-advanced-non-small-cell-lung-cance-46405https://curecurrent.com/trials/rational-epigenetic-immunotherapy-for-second-line-therapy-in-patients-with-nsclc-precise-trial-46406https://curecurrent.com/trials/intraoperative-frozen-section-pathology-to-diagnose-the-iaslc-grades-for-lung-adenocarcinoma-ectop-1014-46407https://curecurrent.com/trials/jk-1201i-compared-with-topotecan-in-patients-with-relapsed-extensive-stage-small-cell-lung-cancer-46408https://curecurrent.com/trials/phase-2-study-of-s-1-as-2nd-line-therapy-in-advanced-non-small-cell-lung-cancer-46409https://curecurrent.com/trials/comparison-of-ligasure-to-conventional-electrocoagulation-in-video-assisted-thoracoscopic-surgery-lobectomy-46410https://curecurrent.com/trials/scion-sabr-and-checkpoint-inhibition-of-nsclc-46411https://curecurrent.com/trials/phase-iii-study-to-determine-the-efficacy-of-durvalumab-in-combination-with-chemotherapy-in-completely-resected-stage-ii-46412https://curecurrent.com/trials/stereotactic-body-radiotherapy-for-oligo-progression-metastatic-non-small-cell-lung-cancer-46413https://curecurrent.com/trials/cryoablation-with-or-without-serplulimab-in-treating-patients-with-stage-i-iia-non-small-cell-lung-cancer-46414https://curecurrent.com/trials/efficacy-and-safety-of-combination-therapy-of-sintilimab-and-chemotherapy-with-cryoablation-in-nsclc-46415https://curecurrent.com/trials/evaluation-of-the-contribution-of-a-dematerialized-video-pedagogical-support-in-the-care-pathway-of-lung-cancer-surgery-46416https://curecurrent.com/trials/to-determine-safe-and-effective-dose-of-sotatercept-for-the-treatment-of-chemotherapy-induced-anemia-in-participants-wit-46417https://curecurrent.com/trials/next-generation-chest-x-ray-tomosynthesis-for-screening-of-lung-cancer-46418https://curecurrent.com/trials/cranial-radiotherapy-plus-chemoimmunotherapy-in-untreated-driver-mutation-negative-nsclc-with-stable-brain-metastasis-46419https://curecurrent.com/trials/standalone-observational-study-assessing-the-performance-of-an-ai-ml-tech-based-samd-on-chest-ldct-images-reality-46420https://curecurrent.com/trials/gsk3359609-plus-tremelimumab-for-the-treatment-of-advanced-solid-tumors-46421https://curecurrent.com/trials/efficacy-and-safety-study-of-navarixin-mk-7123-in-combination-with-pembrolizumab-mk-3475-in-adults-with-selected-advance-46422https://curecurrent.com/trials/the-impact-of-covid-19-pandemic-on-cancer-care-46423https://curecurrent.com/trials/multidisciplinary-prehabilitation-management-pathway-and-network-platform-construction-46424https://curecurrent.com/trials/eb-oct-biopsy-guidance-of-lung-cancer-46425https://curecurrent.com/trials/switch-maintenance-gemcitabine-after-first-line-chemotherapy-in-patients-with-malignant-pleural-mesothelioma-46426https://curecurrent.com/trials/incidence-and-characterization-of-drivers-oncogenes-in-the-population-with-lung-cancer-afferents-to-the-cancer-institute-46427https://curecurrent.com/trials/study-of-comparing-saf-189s-with-crizotinib-in-first-line-alk-positive-advanced-and-metastatic-nsclc-46428https://curecurrent.com/trials/analgesic-efficacy-of-an-opioid-free-postoperative-pain-management-strategy-versus-a-conventional-opioid-based-strategy-46429https://curecurrent.com/trials/a-safety-tolerability-and-preliminary-efficacy-evaluation-of-cc-90011-given-in-combination-with-cisplatin-and-etoposide-46430https://curecurrent.com/trials/befotertinib-and-icotinib-in-treatment-naive-patients-with-advanced-egfr-mutant-lung-cancer-46431https://curecurrent.com/trials/prehab-for-lung-and-esophageal-cancer-46432https://curecurrent.com/trials/ensartinib-as-adjuvant-treatment-in-anaplastic-lymphoma-kinase-alk-positive-non-small-cell-lung-cancer-46433https://curecurrent.com/trials/quilt-2-013-first-line-treatment-for-extensive-stage-small-cell-lung-cancer-46434https://curecurrent.com/trials/decide-developing-tools-for-lung-cancer-screening-discussion-improvement-46435https://curecurrent.com/trials/befotertinib-adjuvant-therapy-in-stage-ia2-ib-nsclc-patients-46436https://curecurrent.com/trials/sirolimus-and-durvalumab-for-the-treatment-of-stage-i-iiia-non-small-cell-lung-cancer-46437https://curecurrent.com/trials/biomarkers-of-response-to-pembrolizumab-combined-with-chemotherapy-in-non-small-cell-lung-cancer-keynote-782-mk-3475-782-46438https://curecurrent.com/trials/comparison-between-different-ways-for-using-lidocaine-during-fb-46439https://curecurrent.com/trials/intra-tumor-injection-of-drug-eluting-microspheres-with-multiple-drugs-46440https://curecurrent.com/trials/osimertinib-and-navitoclax-in-treating-patients-with-egfr-positive-previously-treated-advanced-or-metastatic-non-small-c-46441https://curecurrent.com/trials/immunotherapy-and-carbon-ion-radiotherapy-in-solid-cancers-with-stable-disease-46442https://curecurrent.com/trials/efficacy-and-safety-study-of-durvalumab-maintenance-in-patients-with-stage-iii-non-small-cell-lung-cancer-46443https://curecurrent.com/trials/everolimus-and-vatalanib-in-treating-patients-with-advanced-solid-tumors-46444https://curecurrent.com/trials/hypofraction-radiotherapy-for-limited-stage-small-cell-lung-cancer-46445https://curecurrent.com/trials/utility-of-bronchoscopy-in-patients-with-haemoptysis-and-negative-chest-ct-scan-ulysses-46446https://curecurrent.com/trials/azd9150-plus-durvalumab-alone-or-in-combination-with-chemotherapy-in-patients-with-advanced-solid-tumours-and-in-patient-46447https://curecurrent.com/trials/liquid-biopsies-in-patients-presenting-non-small-cell-lung-cancer-46448https://curecurrent.com/trials/quilt-3-026-amg-655-in-combination-with-amg-479-in-advanced-refractory-solid-tumors-46449https://curecurrent.com/trials/the-study-of-tusamitamab-ravtansine-ibi126-combined-with-sintilimab-and-tusamitamab-ravtansine-ibi126-combined-with-sint-46450https://curecurrent.com/trials/adebrelimab-combined-with-chemotherapy-and-concurrent-sbrt-for-neoadjuvant-treatment-of-limited-stage-small-cell-lung-ca-46451https://curecurrent.com/trials/bronchial-washing-beforeand-after-endobronchial-biopsy-and-bronchial-brushing-46452https://curecurrent.com/trials/pharmacological-ascorbate-for-lung-cancer-46453https://curecurrent.com/trials/srt-for-residual-oligometastases-of-nsclc-after-3rd-generation-egfr-tkis-46454https://curecurrent.com/trials/research-for-the-molecular-imaging-of-the-pd-l1-targeting-tracer-46455https://curecurrent.com/trials/the-bern-rehab-registry-46456https://curecurrent.com/trials/searching-for-predictive-biomarkers-of-efficacy-in-small-cell-lung-cancer-patients-treated-with-chemotherapy-immunothera-46457https://curecurrent.com/trials/reirradiation-dose-escalation-in-thoracic-cancers-46458https://curecurrent.com/trials/csf-ctc-capture-guided-egfr-tki-and-bevacizumab-combination-therapy-in-egfr-mutant-advanced-nsclc-46459https://curecurrent.com/trials/a-rc198-study-in-subjects-with-locally-advanced-unresectable-or-metastatic-solid-tumors-46460https://curecurrent.com/trials/the-impact-of-probiotic-on-survival-and-treatment-response-in-metastatic-non-small-cell-lung-cancer-patients-46461https://curecurrent.com/trials/a-safety-and-efficacy-study-of-bevacizumab-paclitaxel-carboplatin-compared-to-avastin-in-non-small-cell-lung-cancer-46462https://curecurrent.com/trials/efficacy-and-safety-of-serplulimab-with-chemotherapy-and-aspirin-in-untreated-extensive-stage-small-cell-lung-cancer-46463https://curecurrent.com/trials/local-recurrence-prediction-of-by-texture-analysis-derived-from-positron-emission-tomography-pet-ct-imaging-of-non-small-46464https://curecurrent.com/trials/advanced-lung-tumor-treated-by-osimertinib-plus-anlotinib-46465https://curecurrent.com/trials/prime-lung-primary-radiotherapy-in-metastatic-lung-cancer-a-pilot-study-46466https://curecurrent.com/trials/bespoke-study-of-ctdna-guided-immunotherapy-46467https://curecurrent.com/trials/flare-rt-for-patients-with-stage-iib-iiib-non-small-cell-lung-cancer-personalizing-radiation-therapy-using-pet-ct-and-sp-46468https://curecurrent.com/trials/neoadjuvant-hs-10296-almonertinib-therapy-for-potential-resectable-stage-iii-egfr-mutation-positive-non-small-cell-lung-46469https://curecurrent.com/trials/real-life-second-line-epirubicin-paclitaxel-regimen-as-treatment-of-relapsed-small-cell-lung-cancer-epitax-study-46470https://curecurrent.com/trials/real-world-data-on-stage-iii-nsclc-patients-treated-with-durvalumab-after-chemoradiotherapy-in-asia-area-pacific-aa-46471https://curecurrent.com/trials/dietary-intervention-for-nsclc-patients-treated-with-ici-46472https://curecurrent.com/trials/analysis-of-lung-cancer-tissue-with-spatial-frequency-domain-imaging-46473https://curecurrent.com/trials/a-study-of-pf-06463922-an-alk-ros1-inhibitor-in-patients-with-advanced-non-small-cell-lung-cancer-with-specific-molecula-46474https://curecurrent.com/trials/ast-vac2-vaccine-in-patients-with-non-small-cell-lung-cancer-46475https://curecurrent.com/trials/toripalimab-combined-with-double-platinum-based-chemotherapy-for-initially-unresectable-nsclc-46476https://curecurrent.com/trials/a-study-evaluating-the-safety-pharmacokinetics-and-preliminary-efficacy-of-orally-administered-sm08502-combined-with-hor-46477https://curecurrent.com/trials/promoting-radon-testing-via-smartphone-app-a-clinical-trial-in-a-high-radon-state-46478https://curecurrent.com/trials/testing-the-addition-of-an-experimental-medication-mk-3475-pembrolizumab-to-usual-anti-retroviral-medications-in-patient-46479https://curecurrent.com/trials/bai-bace-for-advanced-lung-squamous-cell-carcinoma-46480https://curecurrent.com/trials/erectile-dysfunctions-gonadotoxicity-and-sexual-health-assessment-in-men-with-lung-cancer-46481https://curecurrent.com/trials/prognostic-value-of-combined-approach-based-on-keap1-nfe2l2-mutations-and-pre-therapeutic-fdg-pet-ct-radiomic-analysis-i-46482https://curecurrent.com/trials/alectinib-in-neo-adjuvant-treatment-of-stage-iii-nsclc-46483https://curecurrent.com/trials/sbrt-combined-with-avelumab-anti-pd-l1-for-management-of-early-stage-non-small-cell-lung-cancer-nsclc-46484https://curecurrent.com/trials/radiotherapy-to-all-residual-lesions-after-chemoimmunotherapy-46485https://curecurrent.com/trials/improving-osimertinib-exposure-and-cost-effectiveness-using-pharmacokinetic-boosting-with-cobicistat-46486https://curecurrent.com/trials/study-to-identify-patients-with-advanced-metastatic-non-small-cell-lung-cancer-nsclc-and-alk-and-ros1-translocation-and-46487https://curecurrent.com/trials/trial-of-chidamide-in-combination-with-envafolimab-in-patients-with-pd-1-inhibitor-resistant-advanced-nsclc-46488https://curecurrent.com/trials/fecal-microbial-transplantation-non-small-cell-lung-cancer-and-melanoma-46489https://curecurrent.com/trials/shr-1210-combined-with-apatinib-in-treatment-of-ed-sclc-after-failure-of-first-line-standard-therapy-46490https://curecurrent.com/trials/efficacy-and-safety-of-concurrent-chemoradiotherapy-with-oral-vinorelbine-in-patients-with-non-small-cell-lung-cancer-46491https://curecurrent.com/trials/prediction-of-mediastinal-station-iv-lymph-node-metastasis-in-non-small-cell-lung-cancer-46492https://curecurrent.com/trials/an-open-label-uncontrolled-study-of-ono-4578-and-ono-4538-in-combination-with-standard-of-care-docetaxel-and-ramucirumab-46493https://curecurrent.com/trials/compare-the-effects-of-preoperative-pulmonary-rehabilitation-exercises-on-postoperative-anxiety-and-muscle-strength-46494https://curecurrent.com/trials/a-study-of-bpi-7711-capsule-in-non-small-cell-lung-cancer-patients-46495https://curecurrent.com/trials/food-reward-in-cachexia-induced-by-acute-or-chronic-disease-46496https://curecurrent.com/trials/effects-of-nurse-led-supportive-care-programme-on-caregiver-burden-and-resilience-of-family-caregivers-46497https://curecurrent.com/trials/perceptions-on-expected-outcomes-of-immunotherapy-in-advanced-cancer-patients-with-poor-performance-status-46498https://curecurrent.com/trials/a-multicenter-randomized-controlled-study-of-interventional-treatment-for-operable-stage-non-small-cell-lung-cancer-with-46499https://curecurrent.com/trials/virtual-personalized-exercise-program-for-lung-cancer-patients-46500https://curecurrent.com/trials/sleep-and-immune-checkpoint-inhibitors-46501https://curecurrent.com/trials/osimertinib-and-abemaciclib-in-egfr-mutant-non-small-cell-lung-cancer-after-osimertinib-resistance-46502https://curecurrent.com/trials/first-nec-gfpc-01-2022-combination-of-durvalumab-with-etoposide-and-platinum-46503https://curecurrent.com/trials/a-phase-2-open-label-study-of-amuvatinib-in-combination-with-platinum-etoposide-chemotherapy-in-small-cell-lung-cancer-46504https://curecurrent.com/trials/surgical-strategy-of-nsclc-patients-after-neo-adjuvant-or-induction-treatment-46505https://curecurrent.com/trials/a-study-of-at13387-in-patients-with-non-small-cell-lung-cancer-nsclc-alone-and-in-combination-with-crizotinib-46506https://curecurrent.com/trials/efficacy-and-biomarker-development-for-lung-cancer-treated-with-immune-checkpoint-inhibitors-46507https://curecurrent.com/trials/nutritional-therapy-enriched-with-omega-3-in-patients-with-lung-resection-46508https://curecurrent.com/trials/prospective-study-of-serum-marker-lncrna-rp5-977b1-in-pulmonary-nodules-46509https://curecurrent.com/trials/a-study-of-ramucirumab-plus-pembrolizumab-in-participants-with-gastric-or-gej-adenocarcinoma-nsclc-transitional-cell-car-46510https://curecurrent.com/trials/booster-dose-trial-46511https://curecurrent.com/trials/a-pilot-window-of-opportunity-study-of-the-anti-pd-1-antibody-pembrolizumab-in-patients-with-resectable-malignant-pleura-46512https://curecurrent.com/trials/broadband-collaborative-pulse-ablation-instrument-treating-malignant-pulmonary-nodules-46513https://curecurrent.com/trials/longitudinal-assessment-of-genomic-alterations-and-clonal-evolution-in-alk-positive-nsclc-galileo-project-46514https://curecurrent.com/trials/adjuvant-benmelstobart-for-stage-ib-grade-3-invasive-lung-adenocarcinoma-46515https://curecurrent.com/trials/a-study-to-evaluate-the-efficacy-of-osimertinib-in-patients-with-egfr-sensitive-mutated-non-small-cell-lung-cancer-progr-46516https://curecurrent.com/trials/cryotechnique-as-a-diagnostic-and-therapeutic-tool-of-endobronchial-tumors-46517https://curecurrent.com/trials/study-comparing-standard-of-care-chemotherapy-with-without-sequential-cytoreductive-surgery-for-patients-with-metastatic-46518https://curecurrent.com/trials/signia-stapler-versus-vessel-sealer-extend-energy-device-with-sureform-stapling-in-robotic-assisted-segmentectomy-46519https://curecurrent.com/trials/a-multicenter-real-world-cohort-study-of-adebrelimab-injection-in-the-treatment-of-extensive-stage-small-cell-lung-cance-46520https://curecurrent.com/trials/ramucirumab-and-atezolizumab-after-progression-on-any-immune-checkpoint-blocker-in-nsclc-46521https://curecurrent.com/trials/breath-analysis-and-arterial-stiffness-in-patients-with-respiratory-diseases-46522https://curecurrent.com/trials/evaluation-of-chest-ct-versus-chest-x-ray-for-lung-surveillance-after-curative-intent-resection-of-high-risk-truncal-ext-46523https://curecurrent.com/trials/from-benchmark-to-surgical-activity-the-role-of-endobronchial-fiducial-markers-for-ground-glass-lung-nodules-resection-46524https://curecurrent.com/trials/a-study-of-cisplatin-pemetrexed-avastin-as-first-line-therapy-46525https://curecurrent.com/trials/a-study-of-hs-20093-vs-active-surveillance-in-limited-stage-small-cell-lung-cancer-46526https://curecurrent.com/trials/effect-of-nutrican-to-improve-nutritional-status-in-cancer-patients-46527https://curecurrent.com/trials/study-to-test-the-safety-and-tolerability-of-pf-07209960-in-advanced-or-metastatic-solid-tumors-46528https://curecurrent.com/trials/a-multicentre-study-on-features-of-the-gut-microbiota-of-patients-with-critical-chronic-diseases-in-china-46529https://curecurrent.com/trials/study-of-low-dose-radiotherapy-ldrt-concurrent-cisplatin-carboplatin-plus-etoposide-with-atezolizumab-for-patients-with-46530https://curecurrent.com/trials/a-study-to-evaluate-the-efficacy-and-safety-of-the-combination-of-glumetinib-and-docetaxel-albumin-bound-verse-docetaxel-46531https://curecurrent.com/trials/genetic-bases-of-neuroendocrine-neoplasms-in-mexican-patients-46532https://curecurrent.com/trials/a-global-study-to-assess-the-effects-of-medi4736-durvalumab-given-as-monotherapy-or-in-combination-with-tremelimumab-det-46533https://curecurrent.com/trials/high-dose-furmonertinib-in-the-treatment-in-patients-with-advanced-metastatic-nsclc-with-progressed-after-first-or-secon-46534https://curecurrent.com/trials/prognostic-significance-of-the-uncertain-resection-in-nsclc-46535https://curecurrent.com/trials/first-in-human-phase-i-ii-study-of-fhnd-9041-in-patients-with-egfr-mutated-advanced-non-small-cell-lung-cancer-46536https://curecurrent.com/trials/neratinib-tablets-monotherapy-for-advanced-solid-tumors-with-her2-mutations-46537https://curecurrent.com/trials/value-of-f-18-fdg-pet-ct-for-the-prediction-of-egfr-mutation-in-lung-cancer-patients-46538https://curecurrent.com/trials/befotertinib-and-icotinib-for-nsclc-with-uncommon-egfr-mutations-46539https://curecurrent.com/trials/efficacy-and-safety-of-high-dose-rate-brachytherapy-with-immunotherapy-and-chemotherapy-as-second-line-treatment-for-adv-46540https://curecurrent.com/trials/first-in-human-dose-escalation-study-of-xmt-1536-in-cancers-likely-to-express-napi2b-46541https://curecurrent.com/trials/imfinzi-study-in-patients-with-extensive-stage-small-cell-lung-cancer-46542https://curecurrent.com/trials/omitting-of-lymphadenectomy-is-acceptable-for-lung-cancer-smaller-than-6-mm-in-solid-size-46543https://curecurrent.com/trials/a-study-of-nbf-006-in-non-small-cell-lung-pancreatic-or-colorectal-cancer-46544https://curecurrent.com/trials/evaluation-of-a-novel-microfluidic-device-to-purify-metastatic-lung-cancer-patients-ctc-circulating-tumoral-cells-46545https://curecurrent.com/trials/chemoimmunotherapy-plus-residual-lesion-irradiation-for-the-treatment-of-extensive-stage-small-cell-lung-cancer-46546https://curecurrent.com/trials/clinical-evaluation-of-the-v5-lu01-ai-software-in-thoracic-ct-for-v5med-inc-46547https://curecurrent.com/trials/impact-of-a-nursing-intervention-in-the-management-of-oncological-patients-with-lung-cancer-under-treatment-with-immunot-46548https://curecurrent.com/trials/a-multi-centre-prospective-non-interventional-study-to-intensively-monitor-the-safety-of-osimertinib-in-clinical-practic-46549https://curecurrent.com/trials/trial-of-pulsed-electric-field-therapy-in-patients-with-late-stage-non-small-cell-lung-cancer-46550https://curecurrent.com/trials/treatment-of-pulmonary-sulcus-pancoast-and-chest-wall-non-small-cell-lung-cancer-employing-radiation-immuno-oncology-and-46551https://curecurrent.com/trials/using-artificial-intelligence-for-the-detection-of-respiratory-diseases-associated-with-pollution-46552https://curecurrent.com/trials/study-of-zirconium-zr-89-crefmirlimab-berdoxam-pet-ct-in-subjects-with-advanced-or-metastatic-malignancies-46553https://curecurrent.com/trials/serplulimab-combined-with-ccrt-for-ls-sclc-46554https://curecurrent.com/trials/predictive-value-of-epicardial-adipose-tissue-for-pulmonary-embolism-and-death-in-patients-with-lung-cancer-46555https://curecurrent.com/trials/neoadjuvant-aliya-pef-soft-tissue-ablation-with-systemic-therapy-in-early-stage-resectable-nsclc-46556https://curecurrent.com/trials/a-study-of-bevacizumab-carboplatin-and-paclitaxel-or-pemetrexed-with-or-without-atezolizumab-in-chemotherapy-na-ve-patie-46557https://curecurrent.com/trials/a-study-to-evaluate-the-safety-tolerability-and-pharmacokinetics-of-hh2710-in-patient-with-advanced-tumors-46558https://curecurrent.com/trials/feasibility-study-of-the-aliya-system-in-the-treatment-of-early-stage-non-small-cell-lung-cancer-46559https://curecurrent.com/trials/biomarker-discovery-in-lung-cancer-malaysia-46560https://curecurrent.com/trials/low-volume-high-intensity-interval-training-in-operated-lung-cancer-patients-46561https://curecurrent.com/trials/a-clinical-study-to-evaluate-the-tolerance-pharmacokinetics-and-efficacy-of-tq-a3334-tablets-46562https://curecurrent.com/trials/a-study-of-non-small-cell-lung-cancer-nsclc-patients-receiving-second-line-nivolumab-monotherapy-in-asia-46563https://curecurrent.com/trials/perioperative-music-therapy-plus-oxycodone-in-perioperative-management-of-lung-surgery-46564https://curecurrent.com/trials/testing-tumor-tissue-and-blood-to-help-select-personalized-treatments-for-patients-with-suspected-lung-cancers-46565https://curecurrent.com/trials/gh21-capsules-for-advanced-solid-tumors-a-study-on-safety-and-early-results-46566https://curecurrent.com/trials/a-study-to-prospectively-validate-blood-markers-associated-with-differences-in-efficacy-of-neoadjuvant-therapy-for-nsclc-46567https://curecurrent.com/trials/double-blind-study-to-evaluate-the-pk-efficacy-safety-and-immunogenicity-of-mb12-versus-keytruda-in-stage-iv-nsclc-46568https://curecurrent.com/trials/a-study-of-atezolizumab-in-combination-with-carboplatin-plus-etoposide-to-investigate-safety-and-efficacy-in-patients-wi-46569https://curecurrent.com/trials/chiauranib-for-advanced-solid-malignant-tumors-and-relapsed-refractory-sclc-46570https://curecurrent.com/trials/modulatory-effect-of-prodigiosin-or-pioglitazone-on-time-and-the-crosstalk-to-immune-checkpoint-protein-s-46571https://curecurrent.com/trials/cervical-video-assisted-thoracoscopic-surgery-c-vats-46572https://curecurrent.com/trials/assessment-of-invasive-mediastinal-staging-in-cn1-lung-cancer-46573https://curecurrent.com/trials/a-study-to-determine-progression-free-survival-pfs-and-evaluate-participant-experience-for-participants-with-metastatic-46574https://curecurrent.com/trials/mass-balance-study-of-14c-chiauranib-46575https://curecurrent.com/trials/the-application-of-rapid-fresh-digital-pathology-on-the-diagnosis-and-biomarker-testing-of-lung-cancer-46576https://curecurrent.com/trials/an-analysis-of-treatment-timelines-for-lung-cancer-patients-across-system-evolutions-46577https://curecurrent.com/trials/the-safety-and-efficacy-of-autologous-transfusion-in-spinal-surgery-for-lung-cancer-with-spinal-metastasis-46578https://curecurrent.com/trials/adequacy-assessment-of-bronchoscopic-biopsy-samples-using-a-novel-instrument-46579https://curecurrent.com/trials/a-review-of-low-dose-ct-lung-cancer-screenings-in-a-community-based-healthcare-system-with-high-incidence-46580https://curecurrent.com/trials/real-world-study-in-locally-advanced-or-metastatic-nsclc-patients-progressed-from-first-line-egfr-tki-therapy-46581https://curecurrent.com/trials/relationship-between-immunity-and-metabolism-in-patients-receiving-immune-checkpoint-inhibitors-for-advanced-cancer-rime-46582https://curecurrent.com/trials/dynamic-perfusion-computed-tomography-in-patients-with-localized-non-small-cell-lung-cancer-46583https://curecurrent.com/trials/phase-3-study-evaluating-efficacy-safety-and-pharmacokinetics-of-trilaciclib-in-small-cell-lung-cancer-patients-46584https://curecurrent.com/trials/ro5126766-for-patients-with-advanced-kras-mutant-lung-cancer-46585https://curecurrent.com/trials/a-study-with-bpi-1178-and-osimertinib-in-advanced-non-small-cell-lung-cancer-patients-with-egfr-mutations-46586https://curecurrent.com/trials/added-value-of-pet-ct-in-lung-cancer-46587https://curecurrent.com/trials/study-of-irinotecan-liposome-injection-as-second-line-regimen-in-patients-with-small-cell-lung-cancer-sclc-46588https://curecurrent.com/trials/lung-cancer-screening-in-a-population-exposed-to-occupational-lung-carcinogens-46589https://curecurrent.com/trials/neoadjuvant-intra-tumor-double-immunotherapy-for-lung-cancer-46590https://curecurrent.com/trials/study-of-ro7515629-in-participants-with-hla-g-positive-solid-tumors-46591https://curecurrent.com/trials/testing-the-use-of-targeted-treatment-for-ret-positive-advanced-non-small-cell-lung-cancer-46592https://curecurrent.com/trials/stomach-cancer-exosome-based-detection-46593https://curecurrent.com/trials/a-phase-ib-ii-clinical-study-of-gh21-capsules-combined-with-osimertinib-mesylate-tablets-in-patients-with-nsclc-46594https://curecurrent.com/trials/neoadjuvant-immunotherapy-in-egfr-mutant-localized-nsclc-46595https://curecurrent.com/trials/optimal-postoperative-pain-management-after-lung-surgery-optrial-46596https://curecurrent.com/trials/dasatinib-and-osimertinib-azd9291-in-advanced-non-small-cell-lung-cancer-with-egfr-mutations-46597https://curecurrent.com/trials/efficacy-and-safety-study-of-a-new-therapeutic-strategy-in-the-treatment-of-extended-disease-small-cell-lung-cancer-46598https://curecurrent.com/trials/study-of-amg-160-in-subjects-with-non-small-cell-lung-cancer-46599https://curecurrent.com/trials/68ga-fapi-rgd-pet-ct-imaging-in-the-lung-cancer-patients-46600https://curecurrent.com/trials/docetaxel-cisplatin-and-erlotinib-hydrochloride-in-treating-patients-with-stage-i-iii-non-small-cell-lung-cancer-followi-46601https://curecurrent.com/trials/a-study-to-learn-about-how-bay2927088-affects-the-level-of-dabigatran-or-rosuvastatin-in-the-blood-when-these-drugs-are-46602https://curecurrent.com/trials/a-study-to-learn-about-how-food-and-esomeprazole-affect-the-level-of-bay2927088-in-the-blood-when-taken-together-in-heal-46603https://curecurrent.com/trials/covid-19-and-childhood-cancer-46604https://curecurrent.com/trials/a-study-to-learn-about-how-bay2927088-affects-the-level-of-midazolam-in-the-blood-when-both-drugs-are-taken-together-in-46605https://curecurrent.com/trials/apx005m-with-nivolumab-and-cabiralizumab-in-advanced-melanoma-non-small-cell-lung-cancer-or-renal-cell-carcinoma-46606https://curecurrent.com/trials/shr-1316-combined-with-chemotherapy-and-chest-radiotherapy-in-es-sclc-46607https://curecurrent.com/trials/neoadjuvant-adebrelimab-in-resectable-sclc-a-randomized-trial-46608https://curecurrent.com/trials/furmonertinib-combined-with-anlotinib-in-lung-adenocarcinoma-patients-with-egfr-mutations-and-brain-metastases-46609https://curecurrent.com/trials/the-predictive-value-of-proteome-profiling-for-brain-metastasis-in-limited-stage-small-cell-lung-cancer-46610https://curecurrent.com/trials/checkpoint-inhibitor-combinations-therapy-as-first-line-for-inoperable-lung-cancer-via-it-46611https://curecurrent.com/trials/a-prospective-cohort-study-of-neoadjuvant-chemotherapy-plus-sintillumab-in-the-treatment-of-resectable-nsclc-46612https://curecurrent.com/trials/environmental-pollutants-in-copd-and-lung-cancer-46613https://curecurrent.com/trials/collection-of-blood-bone-marrow-tumor-or-tissue-samples-from-patients-with-cancer-to-study-drug-resistance-46614https://curecurrent.com/trials/sakk-17-18-origin-mpm-nsclc-1st-line-gemci-atezo-ph-ii-46615https://curecurrent.com/trials/99mtc-3prgd2-spect-ct-for-integrin-imaging-of-lung-cancer-46616https://curecurrent.com/trials/lat-for-oligoprogressive-nsclc-treated-with-first-line-osimertinib-46617https://curecurrent.com/trials/a-clinical-study-of-tqb2450-combined-with-anlotinib-in-limited-stage-small-cell-lung-cancer-patients-46618https://curecurrent.com/trials/eternals-remote-monitoring-in-lung-cancer-patients-46619https://curecurrent.com/trials/a-single-cell-approach-to-identify-biomarkers-of-efficacy-and-toxicity-for-ici-in-nsclc-46620https://curecurrent.com/trials/targeted-therapy-in-treating-patients-with-incurable-non-small-cell-lung-cancer-with-genetic-mutations-46621https://curecurrent.com/trials/liposomal-irinotecan-combination-regimen-for-first-line-treatment-of-small-cell-lung-cancer-46622https://curecurrent.com/trials/combining-radiosurgery-and-nivolumab-in-the-treatment-of-brain-metastases-46623https://curecurrent.com/trials/risk-factors-for-postoperative-cough-in-patients-undergoing-thoracoscopic-lung-resection-46624https://curecurrent.com/trials/lm-108-antibody-combination-with-sintilimab-for-locally-advanced-or-metastatic-non-small-cell-lung-cancer-46625https://curecurrent.com/trials/study-with-gefitinib-in-combination-with-olaparib-azd2281-versus-gefitinib-alone-46626https://curecurrent.com/trials/osimertinib-and-locally-ablative-radiotherapy-in-patients-with-synchronous-oligo-metastatic-egfr-mutant-nsclc-stereo-46627https://curecurrent.com/trials/a-study-to-explore-the-role-and-impact-of-wearable-smart-devices-in-perioperative-nsclc-patients-46628https://curecurrent.com/trials/accuracy-of-convex-probe-ebus-tbna-versus-fdg-pet-ct-imaging-in-diagnosis-and-staging-of-lung-malignancies-46629https://curecurrent.com/trials/a-study-to-learn-how-bay2927088-is-taken-up-and-handled-by-the-body-in-healthy-male-participants-46630https://curecurrent.com/trials/4d-cbct-and-intrafractional-imaging-for-the-determination-of-the-most-representative-4d-simulation-planning-technique-fo-46631https://curecurrent.com/trials/tgrx-326-pharmacokinetic-drug-interaction-46632https://curecurrent.com/trials/cios-mobile-3d-spin-for-robotic-bronchoscopy-46633https://curecurrent.com/trials/interventional-software-for-multi-immunotherapy-of-solid-tumors-46634https://curecurrent.com/trials/coronavirus-infection-covid-19-and-radical-surgery-in-patients-with-early-stage-lung-cancer-46635https://curecurrent.com/trials/ppio-006-primary-tumor-resection-for-iva-nsclc-46636https://curecurrent.com/trials/study-of-intravenous-telisotuzumab-vedotin-in-combination-osimertinib-or-standard-of-care-chemotherapy-to-assess-change-46637https://curecurrent.com/trials/intratumor-cpg-odn-injection-boosters-immune-killing-against-in-situ-tumor-antigen-release-for-advanced-solid-tumors-46638https://curecurrent.com/trials/srt-combined-with-anlotinib-for-the-treatment-of-brain-metastases-from-non-small-cell-lung-cancer-46639https://curecurrent.com/trials/neoadjuvant-adjuvant-tislelizumab-combined-with-anlotinib-and-platinum-doublet-chemotherapy-with-resectable-nsclc-46640https://curecurrent.com/trials/gpc3-mesothelin-car-t-cells-against-cancers-46641https://curecurrent.com/trials/adebrelimab-apatinib-in-sclc-maintenance-therapy-46642https://curecurrent.com/trials/efficacy-and-safety-of-aldoxorubicin-compared-to-topotecan-in-subjects-with-metastatic-small-cell-lung-cancer-46643https://curecurrent.com/trials/gpc3-mesothelin-claudin18-2-gucy2c-b7-h3-psca-psma-muc1-tgf-her2-lewis-y-axl-egfr-car-t-cells-against-cancers-46644https://curecurrent.com/trials/understanding-lung-cancer-related-risk-factors-and-their-impact-46645https://curecurrent.com/trials/tcr-t-cell-immunotherapy-of-lung-cancer-and-other-solid-tumors-46646https://curecurrent.com/trials/phase-iii-study-to-determine-efficacy-of-durvalumab-in-stage-ii-iii-non-small-cell-lung-cancer-nsclc-after-curative-inte-46647https://curecurrent.com/trials/everolimus-5-mg-vs-10-mg-daily-for-patients-with-neuroendocrine-tumors-46648https://curecurrent.com/trials/trametinib-combined-with-everolimus-and-lenvatinib-for-recurrent-refractory-advanced-solid-tumors-46649https://curecurrent.com/trials/study-of-poziotinib-in-japanese-patients-with-nsclc-46650https://curecurrent.com/trials/study-of-cxcr5-modified-egfr-targeted-car-t-cells-for-advanced-nsclc-46651https://curecurrent.com/trials/gpc3-car-t-cells-for-immunotherapy-of-cancer-with-gpc3-expression-46652https://curecurrent.com/trials/phase-i-study-of-the-bbp-398-in-patients-with-advance-solid-tumors-46653https://curecurrent.com/trials/icages-guided-precision-therapy-for-cancers-in-contrast-to-standard-care-or-ihc-guided-theray-46654https://curecurrent.com/trials/evaluating-the-safety-and-efficacy-of-pembrolizumab-combined-with-mwa-for-advanced-nsclc-46655https://curecurrent.com/trials/pneumonitis-after-radiotherapy-for-lung-cancer-46656https://curecurrent.com/trials/phase-1b-2-study-to-evaluate-abt-101-in-solid-tumor-and-nsclc-patients-46657https://curecurrent.com/trials/hepatic-impairment-study-for-lorlatinib-in-cancer-patients-46658https://curecurrent.com/trials/study-of-eos-448-with-standard-of-care-and-or-investigational-therapies-in-participants-with-advanced-solid-tumors-46659https://curecurrent.com/trials/study-on-the-therapeutic-effect-of-irinotecan-liposomes-in-small-cell-lung-cancer-46660https://curecurrent.com/trials/a-prospective-open-label-single-center-single-arm-phase-ii-clinical-study-of-cadonilimab-ak104-combined-with-monotherapy-46661https://curecurrent.com/trials/a-study-to-learn-about-how-itraconazole-and-carbamazepine-affect-the-level-of-bay2927088-in-the-blood-when-these-drugs-a-46662https://curecurrent.com/trials/observational-bronchoscopy-video-data-collection-study-with-adult-patients-46663https://curecurrent.com/trials/the-effect-of-combined-general-regional-anesthesia-on-cancer-recurrence-in-patients-having-lung-cancer-resections-46664https://curecurrent.com/trials/robotic-surgery-in-pulmonary-metastasectomy-46665https://curecurrent.com/trials/phase-i-ii-trial-in-es-sclc-to-enhance-response-to-atezolizumab-plus-chemotherapy-with-total-body-irradiation-46666https://curecurrent.com/trials/this-study-will-evaluate-the-effect-of-canakinumab-or-pembrolizumab-given-as-monotherapy-or-in-combination-as-neo-adjuva-46667https://curecurrent.com/trials/a-trial-evaluating-the-activity-and-safety-of-combination-between-cabozantinib-and-temozolomide-in-lung-and-gep-nens-pro-46668https://curecurrent.com/trials/a-study-to-determine-safety-of-durvalumab-after-sequential-chemo-radiation-in-patients-with-unresectable-stage-iii-non-s-46669https://curecurrent.com/trials/tumor-cell-plasticity-and-aggressiveness-in-human-non-small-cell-lung-cancer-46670https://curecurrent.com/trials/developing-novel-circulating-epigenetic-biomarkers-for-early-detection-of-lung-cancer-46671https://curecurrent.com/trials/central-nervous-system-efficacy-of-capmatinib-in-nsclc-with-brain-metastases-with-cfdna-positive-met-alterations-46672https://curecurrent.com/trials/phase-ii-trial-of-almonertinib-plus-lastet-for-egfr-non-small-cell-lung-cancer-46673https://curecurrent.com/trials/management-of-dyspnea-use-of-hand-held-fan-46674https://curecurrent.com/trials/cadonilimab-in-patients-pts-with-advanced-non-small-cell-lung-cancer-nsclc-46675https://curecurrent.com/trials/durvalumab-combined-with-chemoradiotherapy-for-limited-stage-small-cell-lung-cancer-camel-01-46676https://curecurrent.com/trials/ask120067-versus-gefitinib-as-first-line-treatment-for-egfrm-locally-advanced-or-metastatic-nsclc-46677https://curecurrent.com/trials/biochemical-role-of-long-non-coding-rna-malat-1-and-serum-tumor-necrosis-factor-alpha-in-bronchial-asthma-patients-46678https://curecurrent.com/trials/induction-of-sensecence-using-dexamethasone-to-re-sensitize-nsclc-to-anti-pd1-therapy-46679https://curecurrent.com/trials/trial-of-artificial-intelligence-for-chest-radiography-46680https://curecurrent.com/trials/trametinib-plus-anlotinib-combined-with-tislelizumab-in-kras-mutant-nsclc-46681https://curecurrent.com/trials/study-of-tpx-0046-a-ret-src-inhibitor-in-adult-subjects-with-advanced-solid-tumors-harboring-ret-fusions-or-mutations-46682https://curecurrent.com/trials/a-study-of-shr-a1811-in-subjects-with-advanced-non-small-cell-lung-cancer-46683https://curecurrent.com/trials/gi-organ-tracking-via-balloon-applicators-46684https://curecurrent.com/trials/lunglb-in-subjects-presenting-with-indeterminate-pulmonary-nodules-46685https://curecurrent.com/trials/high-flow-nasal-oxygen-during-rigid-bronchoscopy-under-general-anesthesia-a-randomized-controlled-trial-46686https://curecurrent.com/trials/phase-1-2-trial-of-selinexor-kpt-330-with-docetaxel-for-non-small-cell-lung-cancer-nsclc-46687https://curecurrent.com/trials/efficacy-and-safety-of-multimode-thermal-therapy-in-the-treatment-of-early-peripheral-lung-cancer-46688https://curecurrent.com/trials/to-evaluate-the-optimal-timing-of-postoperative-radiotherapy-in-patients-with-iiia-n2-non-small-cell-lung-cancer-46689https://curecurrent.com/trials/clinical-study-of-trop2-car-nk-in-the-treatment-of-relapsed-refractory-non-small-cell-lung-cancer-nsclc-46690https://curecurrent.com/trials/gumarontinib-combined-with-3rd-egfr-tki-in-patients-with-non-small-cell-lung-cancer-46691https://curecurrent.com/trials/clinical-implementation-of-tnm-immunoscore-in-resected-non-small-cell-lung-cancer-46692https://curecurrent.com/trials/capmatinib-plus-trametinib-for-the-treatment-of-metastatic-non-small-cell-lung-cancer-with-met-exon-14-skipping-mutation-46693https://curecurrent.com/trials/evaluation-of-the-synergistic-impact-of-needle-and-forceps-biopsy-with-electromagnetic-navigation-bronchoscopy-46694https://curecurrent.com/trials/ga-68-fapi-pet-before-immunotherapy-46695https://curecurrent.com/trials/observation-on-the-frailty-status-of-lung-cancer-patients-46696https://curecurrent.com/trials/study-of-pemetrexed-platinum-chemotherapy-with-or-without-pembrolizumab-mk-3475-in-participants-with-first-line-metastat-46697https://curecurrent.com/trials/local-ablative-therapy-for-treatment-of-oligoprogressive-egfr-mutated-non-small-cell-lung-cancer-after-treatment-with-os-46698https://curecurrent.com/trials/efficacy-of-platinum-based-chemotherapy-plus-immune-checkpoint-inhibitors-for-egfr-alk-ros1-mutant-lung-cancer-46699https://curecurrent.com/trials/a-phase-ii-study-to-determine-the-preliminary-efficacy-of-novel-combinations-of-treatment-in-patients-with-platinum-refr-46700https://curecurrent.com/trials/efficacy-and-safety-of-modified-si-jun-zi-tang-in-perioperative-nsclc-treatment-46701https://curecurrent.com/trials/phase-ii-study-of-durvalumab-medi4736-tremelimumab-in-pulmonary-sarcomatoid-carcinoma-46702https://curecurrent.com/trials/pre-vent-study-in-hospitalized-patients-with-severe-covid-19-with-or-without-cancer-46703https://curecurrent.com/trials/develop-and-test-the-effects-of-the-computer-assisted-opd-copsccp-on-early-stage-lung-cancer-patients-46704https://curecurrent.com/trials/lurbinectedin-combined-with-durvalumab-in-pre-treated-patients-with-extensive-stage-small-cell-lung-cancer-46705https://curecurrent.com/trials/treatment-response-adapted-hybrid-radiotherapy-in-metastatic-non-small-cell-lung-cancer-receiving-first-line-immunothera-46706https://curecurrent.com/trials/artificial-intelligence-in-lung-cancer-screening-46707https://curecurrent.com/trials/study-of-srf617-in-patients-with-advanced-solid-tumors-46708https://curecurrent.com/trials/study-of-adxs-503-with-or-without-pembro-in-subjects-with-metastatic-non-small-cell-lung-cancer-46709https://curecurrent.com/trials/improvement-of-personalized-lung-cancer-care-through-digital-connection-and-patient-participation-diginet-46710https://curecurrent.com/trials/cd34-malignant-stem-cell-selection-for-patients-receiving-allogenic-stem-cell-transplant-46711https://curecurrent.com/trials/crizotinb-or-standard-chemotherapy-in-met-exon-14-skipping-advanced-nsclc-46712https://curecurrent.com/trials/anlotinib-plus-immune-checkpoint-inhibitors-for-lung-cancer-46713https://curecurrent.com/trials/chemotherapy-with-or-without-immune-checkpoint-inhibitors-for-lung-cancer-46714https://curecurrent.com/trials/differentiating-the-invasiveness-of-lung-adenocarcinoma-by-dual-energy-ct-parameter-46715https://curecurrent.com/trials/efficacy-and-resistance-mechanisms-of-ip-in-nsclc-with-leptomeningeal-metastases-46716https://curecurrent.com/trials/clinical-trial-of-telenursing-for-monitoring-supportive-care-needs-in-patients-with-lung-cancer-and-melanoma-candidates-46717https://curecurrent.com/trials/patient-derived-organoids-of-lung-cancer-to-test-drug-response-46718https://curecurrent.com/trials/pattern-of-use-and-safety-effectiveness-of-nivolumab-in-routine-oncology-practice-46719https://curecurrent.com/trials/a-dose-escalation-study-of-l-dos47-in-recurrent-or-metastatic-non-squamous-nsclc-46720https://curecurrent.com/trials/segmentectomy-for-ground-glass-dominant-invasive-lung-cancer-ectop-1012-46721https://curecurrent.com/trials/t-cell-repertoire-sequencing-assessing-pembrolizumab-efficacy-in-advanced-non-small-lung-cancer-46722https://curecurrent.com/trials/the-shared-project-lung-cancer-screening-for-african-american-men-aam-46723https://curecurrent.com/trials/same-day-discharge-for-wedge-resection-46724https://curecurrent.com/trials/anti-pd-1-and-vegf-bispecific-antibody-ak112-in-combination-with-chemotherapy-in-patients-with-es-sclc-46725https://curecurrent.com/trials/an-exploratory-study-of-efficacy-and-safety-of-iruplinalkib-tablets-in-patients-with-ros1-positive-non-small-cell-lung-c-46726https://curecurrent.com/trials/a-randomised-phase-ii-trial-of-osimertinib-with-or-without-srs-for-egfr-mutated-nsclc-with-brain-metastases-46727https://curecurrent.com/trials/using-infrared-spectroscopy-to-analyze-volatile-organic-compounds-vocs-in-the-breath-of-patients-with-lung-cancer-46728https://curecurrent.com/trials/osimertinib-and-etoposide-as-first-line-treatment-in-osimertinib-resistant-advanced-egfr-mutant-nsclc-46729https://curecurrent.com/trials/the-efficacy-and-safety-of-lmv-12-combined-with-osimertinib-in-nsclc-46730https://curecurrent.com/trials/immune-treatment-of-brain-metastasis-of-lung-cancer-combined-with-large-segmentation-precision-radiotherapy-46731https://curecurrent.com/trials/mechanism-study-to-investigate-difference-in-efficacy-of-neoadjuvant-chemoimmunotherapy-in-lung-squamous-cell-carcinoma-46732https://curecurrent.com/trials/pembrolizumab-plus-bevacizumab-and-chemotherapy-for-alk-rearranged-nsclc-with-persistent-5-alk-46733https://curecurrent.com/trials/a-study-of-sbrt-combined-with-puterizumab-in-intrapulmonary-metastasis-from-nsclc-46734https://curecurrent.com/trials/pulmonary-sarcomatoid-medi4736-treme-46735https://curecurrent.com/trials/evaluate-the-mediators-of-sensitivity-and-resistance-to-nivolumab-plus-ipilimumab-in-patients-with-advanced-nsclcs-46736https://curecurrent.com/trials/jdq443-for-kras-g12c-nsclc-brain-metastases-46737https://curecurrent.com/trials/neoadjuvant-therapy-with-toripalimab-and-js004-combined-with-etoposide-and-platinum-chemotherapy-for-limited-stage-small-46738https://curecurrent.com/trials/3d-reconstruction-in-video-assisted-thoracoscopic-surgery-vats-segmentectomy-46739https://curecurrent.com/trials/safety-and-feasibility-of-surgery-after-conversion-therapy-for-locally-advanced-and-advanced-nsclc-46740https://curecurrent.com/trials/the-impact-of-physical-activity-on-the-postoperative-symptoms-complications-and-quality-of-life-among-lung-cancer-46741https://curecurrent.com/trials/l-til-plus-tislelizumab-for-pd1-antibody-resistant-ansclc-46742https://curecurrent.com/trials/closed-vs-open-face-masks-for-cranial-radiotherapy-46743https://curecurrent.com/trials/a-study-comparing-neoadjuvant-chemoimmunotherapy-and-immuno-consolidationafter-compared-with-immunoconsolidation-after-r-46744https://curecurrent.com/trials/clinical-significance-of-circulating-tumor-cell-in-non-small-cell-lung-cancer-46745https://curecurrent.com/trials/a-comparison-of-silicone-versus-polyvinylchloride-pvc-drains-following-vats-lobectomy-46746https://curecurrent.com/trials/symptom-patterns-and-life-with-longer-term-covid-19-in-children-and-young-people-splat-19-cohort-qualitative-study-46747https://curecurrent.com/trials/cadonilimab-plus-chemotherapy-as-first-line-treatment-for-pd-l1-negative-nsclc-46748https://curecurrent.com/trials/recurrent-predictive-power-of-circulating-tumor-cells-for-non-small-cell-lung-cancer-patients-46749https://curecurrent.com/trials/a-prospective-interventional-study-on-early-screening-for-lung-cancer-using-liquid-biopsy-46750https://curecurrent.com/trials/a-prospective-multicenter-non-interventional-real-world-study-to-characterize-changes-in-molecular-markers-after-three-w-46751https://curecurrent.com/trials/stereotactic-radiation-therapy-and-ipilimumab-in-treating-patients-with-metastatic-melanoma-46752https://curecurrent.com/trials/safety-and-tolerability-of-abm-1310-in-patients-with-advanced-solid-tumors-46753https://curecurrent.com/trials/developing-a-machine-learning-model-to-predict-pleural-adhesion-preoperatively-using-pleural-ultrasound-46754https://curecurrent.com/trials/a-study-of-atezolizumab-in-combination-with-bevacizumab-in-patients-with-egfr-mutation-positive-stage-iiib-iv-non-squamo-46755https://curecurrent.com/trials/axalimogene-filolisbac-adxs11-001-high-dose-in-women-with-human-papillomavirus-hpv-cervical-cancer-46756https://curecurrent.com/trials/an-exploratory-study-of-the-effects-of-nivolumab-combined-with-ipilimumab-in-patients-with-treatment-naive-stage-iv-or-r-46757https://curecurrent.com/trials/effect-of-vitamin-c-on-postoperative-pulmonary-complications-after-intracranial-tumor-surgery-46758https://curecurrent.com/trials/exploration-of-optical-coherence-tomography-guided-transbronchial-biopsy-in-peripheral-pulmonary-lesions-46759https://curecurrent.com/trials/a-prospective-single-arm-phase-ii-clinical-trial-to-evaluate-the-efficacy-and-safety-of-tafolecimab-and-sintilimab-combi-46760https://curecurrent.com/trials/99mtc-68ga-labeled-anti-pd-l1-sdab-in-assessment-of-pd-l1-expression-in-nsclc-46761https://curecurrent.com/trials/oral-iloprost-for-the-prevention-of-lung-cancer-in-former-smokers-46762https://curecurrent.com/trials/comparing-valve-regulated-pleural-drainage-to-traditional-closed-chest-tube-drainage-46763https://curecurrent.com/trials/effects-of-prehabilitation-on-postoperative-recovery-46764https://curecurrent.com/trials/supplementation-of-n-3-pufa-in-the-modulation-of-lean-mass-in-patients-with-lung-cancer-receiving-a-high-protein-diet-46765https://curecurrent.com/trials/observational-study-of-afatinib-30-mg-daily-46766https://curecurrent.com/trials/efficacy-study-of-a-selective-chest-wall-restriction-belt-in-postoperative-of-lung-resection-46767https://curecurrent.com/trials/evaluation-of-response-by-flt-pet-in-mesothelioma-46768https://curecurrent.com/trials/predicting-response-to-neoadjuvant-atezolizumab-plus-carboplatin-nab-paclitaxel-in-resectable-non-squamous-nsclc-46769https://curecurrent.com/trials/surufatinib-combined-with-tislelizumab-in-advanced-lung-cancer-with-neuroendocrine-differentiation-46770https://curecurrent.com/trials/clinical-study-of-18f-alfatide-injection-pet-ct-46771https://curecurrent.com/trials/use-of-the-adl-glittre-test-in-the-pre-and-postoperative-period-of-patients-with-lung-cancer-46772https://curecurrent.com/trials/study-of-cadonilimab-combined-with-chemotherapy-in-recurrent-refractory-pleural-mesothelioma-46773https://curecurrent.com/trials/phase-ii-nivolumab-and-ramucirumab-for-patients-with-previously-treated-mesothelioma-46774https://curecurrent.com/trials/relation-between-tumor-draining-lymph-nodes-metastasis-pattern-and-non-small-cell-lung-cancer-neoadjuvant-immunotherapy-46775https://curecurrent.com/trials/heart-rate-variability-vagus-nerve-and-cancer-46776https://curecurrent.com/trials/real-life-study-with-nivolumab-bms-936558-in-advanced-nsclc-patients-after-prior-chemotherapy-46777https://curecurrent.com/trials/comparison-of-standard-dose-alectinib-to-alectinib-in-adjusted-dose-based-on-alectinib-bloodlevels-46778https://curecurrent.com/trials/cilengitide-and-whole-brain-radiation-therapy-in-treating-patients-with-brain-metastases-from-lung-cancer-46779https://curecurrent.com/trials/a-trial-of-pf-07901800-tti-621-for-patients-with-hematologic-malignancies-and-selected-solid-tumors-46780https://curecurrent.com/trials/a-retrospective-study-of-the-efficacy-and-safety-of-lolatinib-in-alk-nsclc-patients-with-brain-or-meningeal-metastasis-46781https://curecurrent.com/trials/observation-on-the-therapeutic-effect-of-huaier-granules-in-the-adjuvant-treatment-of-non-small-cell-lung-cancer-after-r-46782https://curecurrent.com/trials/prospective-cohort-of-diagnostic-bronchoscopy-for-peripheral-lung-lesions-46783https://curecurrent.com/trials/patient-derived-organoid-drug-sensitivity-guided-treatment-for-recurrent-small-cell-lung-cancer-46784https://curecurrent.com/trials/a-radiomic-model-for-risk-of-local-recurrence-and-dfs-for-t3-and-t4-non-small-cell-lung-cancer-46785https://curecurrent.com/trials/patient-derived-organoid-drug-sensitivity-guided-treatment-for-drug-resistant-recurrent-non-small-cell-lung-cancer-46786https://curecurrent.com/trials/rigosertib-plus-nivolumab-for-kras-nsclc-patients-who-progressed-on-first-line-treatment-46787https://curecurrent.com/trials/a-phase-ii-clinical-study-of-cadonilimab-in-treatment-na-ve-or-relapsed-extensive-small-cell-lung-cancer-46788https://curecurrent.com/trials/neoadjuvant-targeted-therapy-in-patients-with-resectable-egfr-mutated-lung-squamous-cell-carcinoma-46789https://curecurrent.com/trials/study-of-carfilzomib-with-irinotecan-in-irinotecan-sensitive-malignancies-and-small-cell-lung-cancer-patients-46790https://curecurrent.com/trials/coronavirus-disease-2019-covid-19-vaccination-in-cancer-patients-46791https://curecurrent.com/trials/shenlingcao-oral-liquid-for-patients-with-stage-ii-or-iiia-nsclc-46792https://curecurrent.com/trials/exploring-the-theragnostic-value-of-osimertinib-in-egfr-mutated-lung-cancer-theros-46793https://curecurrent.com/trials/breathe-easier-ii-a-dyad-based-multiple-behavior-intervention-46794https://curecurrent.com/trials/a-phase-i-clinical-study-of-qlc1101-in-patients-with-advanced-solid-tumors-46795https://curecurrent.com/trials/a-study-of-combining-cabozantinib-and-atezolizumab-for-advanced-metastatic-nsclc-cabatezo-1-46796https://curecurrent.com/trials/erapid-online-symptom-reporting-in-lung-cancer-46797https://curecurrent.com/trials/sentry-study-raman-spectroscopy-on-ex-vivo-lungs-46798https://curecurrent.com/trials/using-microbiome-to-predict-durvalumab-toxicity-in-post-concurrent-chemoradiation-therapy-ccrt-nsclc-patients-46799https://curecurrent.com/trials/cisplatin-docetaxel-and-nintedanib-before-surgery-in-treating-patients-with-previously-untreated-stage-ib-iiia-non-small-46800https://curecurrent.com/trials/tumor-microenvironment-46801https://curecurrent.com/trials/lung-sbrt-motion-management-gcc-1619-46802https://curecurrent.com/trials/palliative-radiotherapy-to-lung-cancer-a-randomized-multicentre-phase-iii-study-46803https://curecurrent.com/trials/phase-2-study-of-brigatinib-in-japanese-participants-with-anaplastic-lymphoma-kinase-alk-positive-non-small-cell-lung-ca-46804https://curecurrent.com/trials/pulmonary-watershed-topographic-map-navigation-for-lung-nodule-resection-46805https://curecurrent.com/trials/selective-hdac6-inhibitor-acy-241-in-combination-with-nivolumab-in-patients-with-unresectable-non-small-cell-lung-cancer-46806https://curecurrent.com/trials/a-clinical-study-on-the-analysis-of-risk-factors-for-the-occurrence-of-pd-1-pd-l1-inhibitor-associated-liver-injury-in-l-46807https://curecurrent.com/trials/life-lung-cancer-immunotherapy-frailty-effect-46808https://curecurrent.com/trials/hhv8-and-solid-organ-transplantation-46809https://curecurrent.com/trials/consolidation-serplulimab-following-concurrent-chemoradiotherapy-for-ls-sclc-patients-46810https://curecurrent.com/trials/first-line-treatment-with-osimertinib-in-egfr-mutated-non-small-cell-lung-cancer-46811https://curecurrent.com/trials/a-first-in-human-fih-combination-treatment-study-with-a-single-dose-level-of-bmc128-46812https://curecurrent.com/trials/qol-after-surgery-and-adjuvant-treatment-46813https://curecurrent.com/trials/observational-study-on-gep-and-pulm-net-treated-at-fpg-46814https://curecurrent.com/trials/tailoring-shared-decision-making-for-lung-cancer-screening-in-persons-living-with-hiv-46815https://curecurrent.com/trials/study-of-ono-4538-in-non-squamous-non-small-cell-lung-cancer-tasuki-52-46816https://curecurrent.com/trials/efficacy-and-safety-of-intraventricule-pemetrexed-disodium-administered-via-ommaya-reservoir-46817https://curecurrent.com/trials/prognostic-and-predictive-factors-in-unresectable-locally-advanced-nec-and-manec-46818https://curecurrent.com/trials/quality-of-life-and-physical-fitness-after-immune-checkpoint-inhibitors-46819https://curecurrent.com/trials/pointing-clinical-cohort-study-of-patients-with-melanoma-and-nsclc-receiving-checkpoint-inhibitors-46820https://curecurrent.com/trials/precision-immuno-oncology-for-advanced-non-small-cell-lung-cancer-patients-with-pd-1-ici-resistance-46821https://curecurrent.com/trials/pembrolizumab-pet-imaging-46822https://curecurrent.com/trials/pembrolizumab-alone-or-sequentially-following-single-fraction-non-ablative-radiation-to-one-of-the-target-lesions-in-pre-46823https://curecurrent.com/trials/phase-ii-anti-pd1-epigenetic-therapy-study-in-nsclc-46824https://curecurrent.com/trials/postoperative-pain-management-on-patients-undergoing-lung-tumor-resection-46825https://curecurrent.com/trials/vaccination-against-covid-19-in-cancer-46826https://curecurrent.com/trials/clinical-study-on-the-prevention-and-treatment-of-postoperative-metastasis-of-lung-cancer-by-fuzheng-quxie-recipe-46827https://curecurrent.com/trials/aumolertinib-with-chemotherapy-or-alone-compared-with-osimertinib-in-patients-with-epidermal-growth-factor-receptor-muta-46828https://curecurrent.com/trials/high-dose-vitamin-c-intravenous-infusion-in-patients-with-resectable-or-metastatic-solid-tumor-malignancies-46829https://curecurrent.com/trials/disposable-powered-articulating-linear-cutter-stapler-in-total-thoracoscopic-anatomic-lobectomy-segmentectomy-46830https://curecurrent.com/trials/neoadjuvant-chemoimmunotherapy-in-stage-iiia-n2iiib-non-small-cell-lung-cancer-46831https://curecurrent.com/trials/rivaroxaban-sotorasib-interaction-study-46832https://curecurrent.com/trials/immunosensitized-radiotherapy-combined-with-evoximab-ak112-and-chemotherapy-neoadjuvant-therapy-for-stage-ii-iii-non-sma-46833https://curecurrent.com/trials/jmt101-combined-with-osimertinib-in-patients-with-stage-b-non-small-cell-lung-cancer-nsclc-characterized-by-epithermal-g-46834https://curecurrent.com/trials/tomivosertib-combined-with-pembrolizumab-in-subjects-with-pd-l1-positive-nsclc-kickstart-46835https://curecurrent.com/trials/phase-i-ii-study-of-sbrt-and-gc4711-for-centrally-located-or-large-nsclc-46836https://curecurrent.com/trials/alkotinib-capsule-in-patients-with-alk-positive-non-small-cell-lung-cancer-previously-treated-with-crizotinib-46837https://curecurrent.com/trials/lifei-xiaoji-wan-treatment-s-of-early-stage-nsclc-and-its-impact-on-the-tumor-microenvironment-46838https://curecurrent.com/trials/d-1553-tablet-versus-docetaxel-injection-for-kras-g12c-mutation-positive-locally-advanced-or-metastatic-non-small-cell-l-46839https://curecurrent.com/trials/prospective-multicenter-cohort-study-to-validate-four-groups-of-biomarkers-for-assessing-lung-cancer-risk-among-patients-46840https://curecurrent.com/trials/a-phase-i-safety-pk-and-pd-study-of-kw-2478-in-patients-with-multiple-myeloma-chronic-lymphocytic-leukaemia-or-b-cell-no-46841https://curecurrent.com/trials/effect-of-low-dose-radiotherapy-on-tumor-immune-microenvironment-in-oligometastases-of-nsclc-after-immunotherapy-46842https://curecurrent.com/trials/snc115-injections-in-patients-with-recurrent-refractory-small-cell-lung-cancer-and-lung-large-cell-neuroendocrine-carcin-46843https://curecurrent.com/trials/two-part-open-label-multi-center-phase-1-2-study-of-biw-8962-as-monotherapy-in-subjects-with-lung-cancer-46844https://curecurrent.com/trials/a-study-of-kw-2478-in-combination-with-bortezomib-in-subjects-with-relapsed-and-or-refractory-multiple-myeloma-46845https://curecurrent.com/trials/irinotecan-hydrochloride-liposome-injection-ly01610-for-small-cell-lung-cancer-46846https://curecurrent.com/trials/a-study-of-ak104-in-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-46847https://curecurrent.com/trials/a-study-to-evaluate-routine-chest-tube-management-after-minimally-invasive-lung-surgery-46848https://curecurrent.com/trials/the-feasibility-of-dynamic-liquid-biopsy-monitoring-during-neoadjuvant-treatment-for-egfr-mutated-nsclc-46849https://curecurrent.com/trials/imm60-and-pembrolizumab-in-melanoma-and-nsclc-46850https://curecurrent.com/trials/impact-of-covid-19-on-lung-cancer-patients-46851https://curecurrent.com/trials/jmt101-in-combination-with-osimertinib-versus-cisplatin-pemetrexed-in-participants-with-locally-advanced-or-metastatic-n-46852https://curecurrent.com/trials/trametinib-plus-anlotinib-in-non-g12c-kras-mutant-nsclc-patients-46853https://curecurrent.com/trials/study-of-nivolumab-for-non-small-cell-lung-cancer-stage-iii-following-neoadjuvant-chemotherapy-plus-nivolumab-and-defini-46854https://curecurrent.com/trials/neoadjuvant-adjuvant-pembrolizumab-plus-chemotherapy-46855https://curecurrent.com/trials/neuroendocrine-transformation-in-rb1-tp53-inactivated-nsclc-46856https://curecurrent.com/trials/a-study-to-evaluate-the-combination-of-platinum-pemetrexed-based-chemotherapy-plus-lorlatinib-in-alk-positive-non-small-46857https://curecurrent.com/trials/a-safety-and-efficacy-study-of-the-combination-of-oral-pf-00299804-and-intravenous-cp-751-871-given-every-3-weeks-46858https://curecurrent.com/trials/nextsteps-intervention-for-advanced-cancer-patients-and-caregivers-46859https://curecurrent.com/trials/phase-2-study-of-glesatinib-sitravatinib-or-mocetinostat-in-combination-with-nivolumab-in-non-small-cell-lung-cancer-46860https://curecurrent.com/trials/caresteps-a-supportive-care-program-for-the-caregivers-of-advanced-lung-cancer-patients-46861https://curecurrent.com/trials/almonertinib-as-first-line-treatment-in-patients-with-egfr-mutations-positive-in-advanced-nsclc-with-brain-metastases-46862https://curecurrent.com/trials/pd-l1-pd-1-inhibitors-plus-chemotherapy-versus-chemotherapy-alone-for-the-neoadjuvant-treatment-of-limited-stage-sclc-46863https://curecurrent.com/trials/molecular-disease-characterization-initiative-mdci-46864https://curecurrent.com/trials/exercise-in-patients-with-advanced-non-small-cell-lung-cancer-46865https://curecurrent.com/trials/a-nested-case-control-study-of-lung-cancer-and-diesel-exhaust-among-non-metal-miners-46866https://curecurrent.com/trials/an-observational-study-to-evaluate-neoadjuvant-nivolumab-opdivo-in-combination-with-platinum-based-chemotherapy-in-non-m-46867https://curecurrent.com/trials/evaluation-of-lung-metastases-based-on-ultrashort-echo-time-mri-46868https://curecurrent.com/trials/relationship-between-hand-dynamometer-measurements-pft-and-mfi-with-postoperative-outcomes-46869https://curecurrent.com/trials/to-establish-a-molecular-typing-system-for-early-diagnosis-of-lung-cancer-46870https://curecurrent.com/trials/the-efficacy-and-safety-of-pd-1-pd-l1-inhibitors-combined-with-centipeda-minima-cm-in-lung-cancer-46871https://curecurrent.com/trials/imaging-biomarkers-for-immune-checkpoint-inhibitor-treatment-in-patients-with-non-small-cell-lung-cancer-46872https://curecurrent.com/trials/targeted-natural-killer-nk-cell-based-adoptive-immunotherapy-for-the-treatment-of-patients-with-non-small-cell-lung-canc-46873https://curecurrent.com/trials/a-randomised-trial-of-chemotherapy-plus-surgery-for-recurrent-non-small-cell-lung-cancer-46874https://curecurrent.com/trials/lmb-100-followed-by-pembrolizumab-in-the-treatment-of-adults-with-mesothelin-expressing-non-squamous-non-small-cell-lung-46875https://curecurrent.com/trials/designing-an-implementation-strategy-for-lung-screening-and-smoking-cessation-treatment-in-community-health-centers-46876https://curecurrent.com/trials/an-exploratory-clinical-study-to-evaluate-the-safety-and-efficacy-of-nk-cells-combined-with-standard-therapy-in-the-trea-46877https://curecurrent.com/trials/osimertinib-plus-dalpiciclib-in-patients-with-egfr-mutant-cdk4-6-pathway-aberrant-advanced-non-small-cell-lung-cancer-fo-46878https://curecurrent.com/trials/clinical-trial-of-tj271-injection-combined-with-pembrolizumab-in-the-treatment-of-advanced-solid-tumors-46879https://curecurrent.com/trials/efficacy-and-safety-of-deb-bace-combined-with-serplulimab-in-first-line-treatment-of-sclc-46880https://curecurrent.com/trials/pilot-trial-of-e-cigarettes-in-pts-diagnosed-with-cancer-of-the-head-neck-and-lung-46881https://curecurrent.com/trials/exercise-intervention-after-lung-cancer-surgery-46882https://curecurrent.com/trials/real-world-study-of-lolatinib-for-advanced-alk-nsclc-patients-46883https://curecurrent.com/trials/a-study-to-investigate-the-safety-and-efficacy-of-gb1211-a-galectin-3-inhibitor-in-combination-with-atezolizumab-in-pati-46884https://curecurrent.com/trials/study-of-pf-07263689-in-participants-with-selected-advanced-solid-tumors-46885https://curecurrent.com/trials/interleukin-7-to-improve-clinical-outcomes-in-lymphopenic-patients-with-covid-19-infection-iliad-7-us-o-46886https://curecurrent.com/trials/ultra-low-dose-ct-and-use-of-iomeron-400-in-pcd-ct-46887https://curecurrent.com/trials/merestinib-in-non-small-cell-lung-cancer-and-solid-tumors-46888https://curecurrent.com/trials/dose-tapering-and-early-discontinuation-to-increase-cost-effectiveness-of-immunotherapy-for-nsclc-46889https://curecurrent.com/trials/h002-in-patients-with-egfr-mutation-locally-advanced-or-metastatic-nsclc-46890https://curecurrent.com/trials/phase-i-iia-study-of-h002-in-nsclc-with-active-egfr-mutation-46891https://curecurrent.com/trials/study-of-tsr-033-with-an-anti-programmed-cell-death-1-receptor-pd-1-in-participants-with-advanced-solid-tumors-46892https://curecurrent.com/trials/surufatinib-combined-with-gemcitabine-plus-nab-paclitaxel-in-locally-advanced-pancreatic-cancer-46893https://curecurrent.com/trials/preoperative-neoadjuvant-immunotherapy-combined-with-chemotherapy-for-stage-unresectable-non-small-cell-lung-cancer-46894https://curecurrent.com/trials/tumor-nutritional-therapy-in-the-first-line-treatment-of-stage-iv-nsclc-46895https://curecurrent.com/trials/a-study-of-avelumab-in-combination-with-axitinib-in-non-small-cell-lung-cancer-nsclc-or-urothelial-cancer-javelin-medley-46896https://curecurrent.com/trials/chronic-myeloid-leukemia-cml-real-life-database-46897https://curecurrent.com/trials/d-0316-in-patients-with-egfr-positive-non-small-cell-lung-cancer-46898https://curecurrent.com/trials/sars-cov-2-donor-recipient-immunity-transfer-46899https://curecurrent.com/trials/an-observational-study-of-furmonertinib-for-egfr-mutation-positive-nsclc-patients-with-brain-metastasis-46900https://curecurrent.com/trials/comparison-of-emergence-and-oxygenation-during-one-lung-ventilation-with-desflurane-and-propofol-anesthesia-46901https://curecurrent.com/trials/survival-validation-and-gene-mutations-of-n-descriptors-in-the-ninth-edition-of-the-tnm-classification-for-lung-cancer-46902https://curecurrent.com/trials/study-to-evaluate-clinical-real-world-outcomes-of-lorlatinib-after-alectinib-in-alk-positive-nsclc-japanese-patients-46903https://curecurrent.com/trials/durvalumab-with-consolidative-radiochemotherapy-and-ablative-stereotactic-radiotherapy-in-oligometastatic-es-sclc-46904https://curecurrent.com/trials/clinical-and-molecular-findings-in-patients-with-cervical-supraclavicular-metastasis-from-non-small-cell-lung-cancer-nsc-46905https://curecurrent.com/trials/dacomitinib-for-treatment-of-patients-in-india-with-metastatic-non-small-cell-lung-cancer-with-egfr-activating-mutations-46906https://curecurrent.com/trials/testing-the-addition-of-radiation-therapy-to-the-immune-therapy-treatment-for-es-sclc-46907https://curecurrent.com/trials/study-to-evaluate-safety-pk-pd-immunogenicity-antitumor-activity-of-msc-1-in-patients-with-adv-solid-tumors-46908https://curecurrent.com/trials/passive-antibodies-against-covid-19-with-evusheld-in-vaccine-non-responsive-cll-46909https://curecurrent.com/trials/feasibility-study-of-the-microwave-ablation-system-for-lung-tissue-ablation-46910https://curecurrent.com/trials/iodine-i-131-monoclonal-antibody-3f8-in-treating-patients-with-central-nervous-system-cancer-or-leptomeningeal-cancer-46911https://curecurrent.com/trials/construction-and-effect-evaluation-of-the-low-load-blood-flow-restriction-training-program-for-lung-cancer-patients-comp-46912https://curecurrent.com/trials/diagnosis-treatment-and-outcome-of-lung-cancer-patients-46913https://curecurrent.com/trials/risk-factors-of-medistinal-metastasis-in-endoscopic-staging-of-lung-cancer-46914https://curecurrent.com/trials/anet-electrosurgery-applicator-pilot-evaluation-study-46915https://curecurrent.com/trials/a-study-of-anti-pd-1-ak105-in-patients-with-metastatic-nonsquamous-non-small-cell-lung-cancer-46916https://curecurrent.com/trials/phase-i-study-of-repotrectinib-and-osimertinib-in-nsclc-patients-46917https://curecurrent.com/trials/clinical-effects-of-absorbable-and-non-absorbable-suture-in-bronchial-sleeve-resection-46918https://curecurrent.com/trials/a-study-of-anti-pd-1-ak105-in-patients-with-metastatic-squamous-non-small-cell-lung-cancer-46919https://curecurrent.com/trials/personalized-anticoagulant-therapy-for-pulmonary-thromboembolism-46920https://curecurrent.com/trials/the-optimal-number-of-fiducial-marker-for-stereotactic-body-radiotherapy-46921https://curecurrent.com/trials/the-biomarker-exploratory-study-in-prospective-multicenter-observational-study-of-atezolizumab-combination-therapy-in-lu-46922https://curecurrent.com/trials/a-phase-1-2-trial-of-trametinib-and-erlotinib-in-patients-with-egfr-mutant-lung-adenocarcinomas-and-acquired-resistance-46923https://curecurrent.com/trials/epoetin-alfa-in-advanced-non-small-cell-lung-cancer-epo-can-20-46924https://curecurrent.com/trials/natural-killer-nk-cell-combined-with-programmed-death-1-pd-1-antibody-as-second-line-therapy-for-advanced-driver-mutatio-46925https://curecurrent.com/trials/prospective-multicenter-observational-study-of-atezolizumab-combination-therapy-in-lung-cancer-j-tail-2-46926https://curecurrent.com/trials/to-evaluate-the-safety-and-tolerability-of-carbognilumab-combined-with-chemotherapy-as-the-first-line-treatment-for-pati-46927https://curecurrent.com/trials/volatolomic-and-proteomic-profile-for-early-diagnosis-of-lung-cancer-46928https://curecurrent.com/trials/anlotinib-combined-with-penpulimab-as-front-line-treatment-in-advanced-non-small-cell-lung-cancer-46929https://curecurrent.com/trials/immune-checkpoint-inhibition-with-lurbinectedin-relapsed-recurrent-sclc-46930https://curecurrent.com/trials/alectinib-induced-endocrine-toxicity-46931https://curecurrent.com/trials/a-study-of-furmonertinib-combined-with-chemotherapy-in-the-treatment-of-nsclc-with-leptomeningeal-metastasis-46932https://curecurrent.com/trials/survival-with-olanzapine-in-patients-with-locally-advanced-or-metastatic-upper-gastrointestinal-and-lung-cancer-46933https://curecurrent.com/trials/thalidomide-prevention-or-treatment-of-camrelizumab-induced-reactive-cutaneous-capillary-endothelial-proliferation-rccep-46934https://curecurrent.com/trials/ladarixin-with-sotorasib-in-advanced-nsclc-phase-ii-46935https://curecurrent.com/trials/preoperative-paravertebral-block-in-cancer-surgery-of-the-lung-46936https://curecurrent.com/trials/adibelimab-famitinib-and-chemotherapy-for-advanced-nsclc-after-pd-1-inhibitor-failure-46937https://curecurrent.com/trials/clinical-utility-for-ion-endoluminal-system-46938https://curecurrent.com/trials/serplulimab-plus-bevacizumab-and-chemotherapy-for-egfr-mutant-metastatic-nsclc-patients-after-egfr-tki-treatment-failure-46939https://curecurrent.com/trials/a-phase-ii-iii-study-of-adebrelimab-in-combination-with-shr-8068-and-chemotherapy-in-advanced-or-metastatic-nsclc-patien-46940https://curecurrent.com/trials/total-body-irradiation-treatments-for-patients-treated-at-european-institute-of-oncology-46941https://curecurrent.com/trials/sabr-atac-a-trial-of-tgf-beta-inhibition-and-stereotactic-ablative-radiotherapy-for-early-stage-non-small-cell-lung-canc-46942https://curecurrent.com/trials/safety-and-efficacy-of-adebrelimab-plus-irinotecan-liposome-ii-with-or-without-famitinib-in-es-sclc-pre-treated-with-imm-46943https://curecurrent.com/trials/a-study-of-trilaciclib-combined-with-chemotherapy-in-the-treatment-of-advanced-nsclc-with-leptomeningeal-metastasis-46944https://curecurrent.com/trials/a-real-world-study-of-adebrelimab-combined-with-chemotherapy-chest-radiotherapy-in-patients-with-extensive-stage-small-c-46945https://curecurrent.com/trials/artificial-intelligence-for-gross-tumour-volume-segmentation-46946https://curecurrent.com/trials/dc-combined-with-icis-in-the-treatment-of-advanced-lung-cancer-resistant-to-icis-46947https://curecurrent.com/trials/radiomics-and-radiogenomics-of-non-small-cell-lung-cancer-46948https://curecurrent.com/trials/a-single-arm-pilot-study-of-first-line-treatment-with-carbognilumab-combined-with-chemotherapy-in-patients-with-stk11-mu-46949https://curecurrent.com/trials/rrx-001-sequentially-with-a-platinum-doublet-or-a-platinum-doublet-in-third-line-or-beyond-in-patients-with-small-cell-l-46950https://curecurrent.com/trials/wtx212a-monotherapy-and-in-combination-with-pd-1-pd-l1-monoclonal-antibody-46951https://curecurrent.com/trials/distributed-learning-of-edic-and-cardiac-dose-effects-in-lung-cancer-46952https://curecurrent.com/trials/assessment-system-of-sarcopenia-in-lung-cancer-patients-46953https://curecurrent.com/trials/a-study-of-trilaciclib-combined-with-chemotherapy-in-the-treatment-of-nsclc-46954https://curecurrent.com/trials/post-marketing-surveillance-of-nintedanib-in-indian-patients-with-non-small-cell-lung-cancer-nsclc-after-first-line-ther-46955https://curecurrent.com/trials/concurrent-chemotherapy-plus-hfr-radiation-therapy-in-inoperable-nsclc-46956https://curecurrent.com/trials/radiogenomics-in-aerodigestive-tract-cancers-46957https://curecurrent.com/trials/differences-in-rate-of-decline-in-ct-defined-skeletal-muscle-mass-and-physical-performance-in-patients-with-advanced-non-46958https://curecurrent.com/trials/abexinostat-in-combination-with-pembrolizumab-in-patients-with-advanced-solid-tumor-malignancies-46959https://curecurrent.com/trials/study-of-navtemadlin-plus-pembrolizumab-as-maintenance-therapy-in-locally-advanced-and-metastatic-non-small-cell-lung-ca-46960https://curecurrent.com/trials/adjuvant-target-therapy-guided-by-ctdna-mrd-in-patients-with-egfr-mutant-ii-iiia-non-small-cell-lung-cancer-ectop-1022-46961https://curecurrent.com/trials/improving-supportive-care-for-patients-with-thoracic-malignancies-46962https://curecurrent.com/trials/selumetinib-in-patients-receiving-pemetrexed-and-platinum-based-chemotherapy-in-advanced-or-metastatic-kras-wildtype-or-46963https://curecurrent.com/trials/chest-drain-removal-intraoperatively-after-thoracoscopic-wedge-resection-46964https://curecurrent.com/trials/high-dose-furmonertinib-versus-osimertinib-in-advanced-egfrm-nsclc-patients-with-brain-metastases-46965https://curecurrent.com/trials/the-efficacy-of-babaodan-capsules-in-preventing-radiation-pneumonia-46966https://curecurrent.com/trials/efficacy-and-safety-of-jmt101-combined-wth-docetaxel-hb1801-in-patients-with-squamous-cell-non-small-cell-lung-cancer-46967https://curecurrent.com/trials/calypso-guided-high-precision-stereotactic-ablative-radiosurgery-for-lung-tumours-using-real-time-tumour-tracking-respir-46968https://curecurrent.com/trials/study-of-oral-cmet-inhibitor-inc280-in-patients-with-egfr-wild-type-wt-advanced-non-small-cell-lung-cancer-nsclc-geometr-46969https://curecurrent.com/trials/organoids-predict-therapeutic-response-in-patients-with-multi-line-drug-resistant-lung-cancer-46970https://curecurrent.com/trials/palbociclib-pd-0325901-for-nsclc-solid-tumors-46971https://curecurrent.com/trials/self-breathe-rct-for-chronic-breathlessness-46972https://curecurrent.com/trials/structuring-of-a-lung-cancer-screening-program-including-clinical-radiological-and-biological-phenotyping-useful-for-the-46973https://curecurrent.com/trials/a-study-to-assess-safety-tolerability-and-pharmacokinetics-of-absk112-in-patients-with-non-small-cell-lung-cancer-46974https://curecurrent.com/trials/can-austrian-lung-specialists-assessments-of-lung-cancer-screening-be-influenced-by-a-fact-box-46975https://curecurrent.com/trials/quantitative-evaluation-of-the-impact-of-relaxing-eligibility-criteria-for-lung-cancer-based-on-real-world-data-46976https://curecurrent.com/trials/laluca-research-platform-a-prospective-analysis-of-lung-cancer-diagnosis-and-management-in-clinical-practice-46977https://curecurrent.com/trials/study-of-core-needle-biopsy-and-cryoablation-of-an-enlarging-tumor-in-patients-with-metastatic-lung-cancer-and-metastati-46978https://curecurrent.com/trials/the-risk-factors-for-acute-radiation-pneumonitis-in-patients-with-prior-receipt-of-immune-checkpoint-inhibitors-46979https://curecurrent.com/trials/a-study-to-evaluate-safety-efficacy-and-pharmacokinetics-in-participants-with-advanced-solid-tumors-46980https://curecurrent.com/trials/ot-101-in-combination-with-pembrolizumab-in-subjects-with-malignant-pleural-mesothelioma-failing-to-respond-to-checkpoin-46981https://curecurrent.com/trials/primary-tumor-radiotherapy-omitting-ctv-for-patients-with-advanced-nsclc-responded-to-immunotherapy-and-chemotherapy-46982https://curecurrent.com/trials/study-of-ly01610-in-patients-with-recurrent-small-cell-lung-cancer-46983https://curecurrent.com/trials/first-in-human-study-of-xmt-1592-in-patients-with-ovarian-cancer-and-nsclc-likely-to-express-napi2b-46984https://curecurrent.com/trials/single-drug-chemotherapy-plus-immunotherapy-in-metastatic-non-small-cell-lung-cancer-elderly-patients-46985https://curecurrent.com/trials/evaluating-shared-decision-making-for-lung-cancer-screening-among-chinese-populations-in-the-united-states-46986https://curecurrent.com/trials/split-course-hypofractionated-radiotherapy-with-concurrent-chemotherapy-in-locally-advanced-non-small-cell-lung-cancer-46987https://curecurrent.com/trials/omitting-ctv-for-locally-advanced-nsclc-responded-to-immunotherapy-and-chemotherapy-46988https://curecurrent.com/trials/oral-chemotherapeutic-drugs-were-analyzed-in-patients-with-driver-gene-negative-locally-advanced-advanced-non-small-cell-46989https://curecurrent.com/trials/chemotherapy-and-atezolizumab-for-patients-with-extensive-stage-small-cell-lung-cancer-sclc-with-untreated-asymptomatic-46990https://curecurrent.com/trials/deep-learning-model-predicts-pathological-complete-response-of-lung-cancer-following-neoadjuvant-immunochemotherapy-46991https://curecurrent.com/trials/a-study-of-hstc810-with-advanced-metastatic-solid-tumors-stcube-001-46992https://curecurrent.com/trials/erector-spinae-plane-block-versus-intercostal-for-vats-46993https://curecurrent.com/trials/osimertinib-with-stereotactic-radiosurgery-srs-in-brain-metastases-from-egfr-positive-nsclc-46994https://curecurrent.com/trials/combined-statin-and-pd-1-pd-l1-inhibitors-in-treating-non-small-cell-lung-cancer-46995https://curecurrent.com/trials/a-study-of-adebrelimab-combined-with-famitinib-and-chemotherapy-in-the-treatment-of-es-sclc-46996https://curecurrent.com/trials/sintilimab-with-pemigatinib-in-patients-with-pd-l1-positive-and-fgfr-mutated-advanced-non-small-cell-lung-cancer-46997https://curecurrent.com/trials/study-of-wm-a1-3389-in-participants-with-advanced-or-metastatic-solid-tumors-and-non-small-cell-lung-cancer-mk-3475-e90-46998https://curecurrent.com/trials/mrd-assay-evaluates-recurrence-and-response-via-a-tumor-informed-assessment-46999https://curecurrent.com/trials/a-study-of-hc-7366-to-establish-the-maximum-tolerated-dose-mtd-and-recommended-phase-2-dose-rp2d-47000